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JOY ELIZABETH KIRKPATRICK. Validation and Development of KDM4B Inhibitors to  
Target Periodontal Disease Progression. (Under the direction of PATRICK WOSTER). 
Periodontal disease (PD) affects nearly half of the adult United States population and is 
characterized by bacterial-driven inflammatory bone loss. Traditional and emerging 
treatments for periodontitis management do not typically target the host immune response, 
which is the major source of tissue damage. The demethylation activity of lysine-specific 
demethylase 1 (KDM1A) at histone 3 lysine 4 leads to a decrease in pro-inflammatory 
cytokine transcription. By contrast, lysine specific demethylase 4B (KDM4B) is a histone 
demethylase that specifically demethylates histone 3 trimethyllysine 9 (H3K9me3). 
Interestingly, previous data has shown that cross talk between these two enzymes leads 
to a balanced system wherein lysine 9 methylation serves as a prerequisite to lysine 4 
demethylation by KDM1A. The studies outlined in this dissertation will exploit this crosstalk 
for the design of new potential therapies for PD. The central hypothesis of this dissertation 
is that promotion of KDM1A activity by introduction of a specific KDM4B inhibitor will 
alleviate PD by controlling the overactive immune system in diseased areas, enabling the 
host to better manage the disease. This hypothesis was tested through completion of the 
following Specific Aims: Specific Aim 1: To mechanistically define the role of KDM4B in 
periodontal inflammation; Specific Aim 2: To design a novel inhibitor of KDM4B for 
adjunctive treatment of PD inflammation, and Specific Aim 3: To evaluate novel and known 
KDM4B inhibitors for in vivo activity as anti-inflammatory agents. KDM4B inhibition 
prevented the A.a-induced immune response in vitro and in vivo. KDM4B inhibition also 
reduced osteoclast formation in vitro and bone loss in vivo. KDM4B activity is heightened 
in periodontal disease in clinical tissues as well as in murine calvarial tissue sections 
treated with A.a. KDM4B inhibition mediated immunosuppression relies on the concurrent 
overactivation of KDM1A. Computational chemical screens identified several hit scaffolds, 
one of which was optimized using phenotypic screen guided binary QSAR. From an 
extensive in silico derivative library, 25 novel derivatives were synthesized, 8 of which 




Chapter 1: Background and Significance 
 
1.1. Periodontal Disease 
1.1.a. Clinical Significance and Epidemiology 
Periodontitis is a chronic oral inflammatory condition that destroys the supporting 
tissues of teeth, resulting in irreversible damage including bone loss and tooth loss. 
Currently, this disease affects 42% of dentate adults in the United States. There is higher 
prevalence of the disease associated with adults 65 years or older, Mexican-Americans, 
non-Hispanic blacks and smokers.1 Severe periodontal disease is estimated by the world 
health organization to be the 11th most prevalent disease globally.2 Although traditional 
therapies performed by clinicians are effective for a large proportion of patients, these 
measures come at a cost, with 20% of out-of-pocket health expenditure coming from 
dental treatment.3 This is largely due to a derisory ability to control the disease which is 
a direct result of our inadequate understanding of the underlying disease 
pathophysiology. 
1.1.b. Clinical Diagnosis 
While a consensus for diagnosis of specific periodontal diseases has been difficult 
to achieve due to the complexity of the disease,4 the American Academy of Periodontology 
suggests that a diagnosis can be reached by a combination of clinical measurements. 
These measurements seek to identify the extent of inflammatory involvement by 
measuring probing depth, clinical attachment loss (CAL) and bleeding on probing (BOP) 
combined with the extent of alveolar bone loss which can be measured radiographically.5 




health or periodontal pocket in disease while applying light pressure. Probing depth 
measures the linear distance from the base of the sulcus or pocket to the gingival margin, 
where a measurement of < 4 mm is considered healthy. Clinical attachment loss measures 
the linear distance from the depth of the sulcus or pocket to the cementoenamel junction 
(CEJ), which may be more accurate as it eliminates variability in clinical crown size, 
accounting for differences in gingival recession and excess between patients. While 
extensive literature supports clinical attachment loss as the most important measurement 
in diagnosis of periodontal disease, this is commonly not measured clinically, and while 
inferior, probing depth is taken in its place.6-7 Nevertheless, increases in these measures 
demonstrate that there has already been apical migration of the connective tissue 
attachment of the periodontal ligament, which connects the cementum of the tooth to 
bone. When the force of tension from the periodontal ligament onto the bone is lost, the 
bone remodels and there is a net loss of bone in the area,8 which can be seen 
radiographically. In a complementary process, inflammatory mediators associated with 
periodontal lesions activate bone resorbing osteoclasts. This combination of events can 
lead to drastic levels of bone loss, which can involve the furcation, result in severe 
fremitus, or result in the ultimate extreme: tooth loss.  
In addition to taking linear measurements to assess alveolar bone loss, soft tissues 
are assessed for bleeding. In an intact gingival sulcus of a healthy patient, junctional 
epithelium serves to protect the underlying connective tissue from exposure to the oral 
environment. Unlike other types of epithelium, junctional epithelium contains relatively few 
desmosomes and occasionally has gap junctions.9 Inter-cellular spacing is also much 




the junctional epithelium has something that resembles a basement membrane, it is 
structurally unique, lacking several major components such as collagen IV and VII. 
Therefore, the normal physical barrier contained within most types of epithelium is not 
existent in the junctional epithelium.10 Because of this, immune cells such as 
polymorphonuclear leukocytes (neutrophils), macrophages, lymphocytes and dendritic 
cells can continuously sample the environment and respond to an overwhelming insult. 
When the inflammatory cells are chronically activated, such as is seen in the presence of 
specific so-called “perio-pathogens” or in the presence of a large mass of plaque or 
calculus, the periodontal ligament collagen fibers detach from the root cementum of the 
tooth, resulting in transformation of the junctional epithelium to long junctional epithelium. 
At this point, the healthy gingival sulcus has fully transformed into a periodontal pocket,  
where overgrowth and leakiness of blood vessels is a common occurrence.11 In the case 
that there is any bleeding at all, this is considered unhealthy and is recorded in the patient’s 
chart. Lastly, plaque index is a measure of the patient’s current plaque load, which has 
been established with little debate as the initial causative agent of periodontal disease. 
Overall, clinical measurements to diagnose periodontal disease aim to evaluate three 
main factors: oral hygiene, inflammation and bone loss. 
According to the 1999 consensus report on periodontal classifications,12 
periodontal disease is classified based on whether it is chronic or aggressive, and again 
by whether it is generalized or localized.13 Aggressive periodontitis presents in patients 
who are otherwise healthy, but exhibit rapid bone and attachment loss. This is thought to 
be attributed to an underlying genetic predisposition, as it is seen in families.14 Although 




have a disproportionate immune response to the amount of plaque present with hyper-
responsive macrophages.15 In chronic periodontitis, the amount of bone and attachment 
loss directly correlates with the plaque load and subgingival calculus is commonly present. 
This form of disease can be associated with other systemic diseases and has a slow rate 
of progression, According to this classification system, both forms of disease can either 
be localized, where ≤ 30% of total sites are diseased, or generalized, where >30% of sites 
are diseased. While this classification system proved useful to clinicians and researchers 
for several years, it did not address the complexity and confounding variables within 
periodontal diseases, nor did it have a valid justification for differentiating between chronic 
and aggressive periodontal disease. 
In 2018, a new international classification system for periodontal disease was 
developed following the 2017 World Workshop on the Classification of Periodontal and 
Peri‐Implant Diseases and Conditions.16 This current classification system groups chronic 
and aggressive periodontitis under one category of disease (periodontitis) and has only 
two additional disease classifications that can be considered periodontal disease: 
periodontitis as a direct manifestation of systemic disease, and necrotizing periodontitis. 
Within periodontitis, disease is further defined by stages I through IV, and grades A, B, 
and C. Stages increase based on severity, complexity and extent and distribution of 
disease, and grades increase based on both direct and indirect evidence of progression 
as well as risk factors. Necrotizing periodontal disease is periodontal disease where there 
is necrosis of the papilla, bleeding and pain and is classified into two categories based on 
the affected patient population: chronically, severely compromised patients and 




of systemic disease is diagnosed by identification of a rare host immune modulating 
systemic disease. In the absence of a rare systemic disease or necrotizing lesion, where 
there is an interdental CAL at ≥ 2 non-adjacent teeth or CAL of ≥ 3mm at ≥2 teeth, the 
disease is considered periodontitis and should be staged and graded according to its 
characteristics. In addition to these three main forms of periodontal disease, additional 
separate diagnoses exist for periodontal abscesses as well as endo-periodontal lesions. 
In a periodontal abscess, there is localized accumulation of pus within the periodontal 
pocket. In endo-periodontal lesions, there is a pathologic communication between 
periodontal and pulpal tissues where either one causes the other or they occur 
simultaneously.16 While the clinical diagnosis of aggressive periodontitis has been 
eliminated, the characteristic presentation can be alternatively described as Stage III.C 
with a molar incisor pattern.16 Periodontal disease classification has undergone many 
changes over the years and will continue to evolve as more information is discovered. 
1.1.c. Pathogenesis: Introduction 
 The specific pathway that leads to initiation and progression of periodontal disease 
has been debated for decades. In the 1970s, several groups had committed to the “co-
destructive factor” hypothesis,17 suggesting that traumatic occlusion or other mild injuries 
adjacent to plaque and calculus was enough to initiate destruction of periodontal tissues.18-
19 By 1980, the critical importance of the exaggerated immune response in the etiology of 
periodontal destruction had been established. The co-destructive factor hypothesis was 
disproved; removing the source of trauma in the presence of inflammation had no effect 
on bone regeneration or connective tissue attachment, while resolution of inflammation in 




a “continuous disease” hypothesis, where the disease would progress continuously until 
intervention or tooth loss. Unfortunately, inflammation is a very complex process, and the 
periodontium is a very complex site, and newer studies were suggesting that periodontal 
disease was a dynamic, multi-factorial process that wasn’t continuous or predictable.24-25 
In 1984, Socransky et. al suggested a systemic factor for the progression of periodontal 
disease for the first time, pointing to a correlation of periodontally destructive events with 
specific life events such as pregnancy. This breakthrough study also fed into the 
conversation regarding different forms of periodontal disease, and the importance in 
distinguishing between them for accuracy of further research.26 
What has remained constant over the years is the importance of plaque and 
calculus for the initiation of periodontal disease. The development of calculus generally 
progresses through three distinct phases: pellicle formation, plaque development and 
calcification. The pellicle is a thin biofilm layer of mainly protein that forms on teeth 
naturally throughout the day. Plaque on the other hand, is a microenvironment that 
contains living microorganisms such as bacteria, viruses and fungi as well as an 
extracellular matrix of salivary proteins and food particles.27 This microenvironment has 
the potential to undergo specific changes which confer benefits to the survival of more 
pathogenic bacteria.28 For periodontal disease, potential for true detriment depends 
primarily on the third stage, calcification. Calcium salts from saliva and dietary sources 
can incorporate into the intricate plaque lattice and form a mineralized and tightly adhered 
mass to the tooth structure. This allows for adherence of new biofilm upon its surface, 
leading to a host tissue response in the form of immune activation as well as detachment 




viable microbial environments from things that might otherwise keep them at bay.29 
Calculus is tightly adhered to the tooth structure, requiring professional removal by 
clinicians using either scalers or ultrasonic cleaners. Because of this well-defined 
progression of events centered on biofilms, it is of critical importance to educate patients 
on at home and in office oral hygiene measures. The use of soft-bristled toothbrushes, 
floss and regular dental visits may have the potential to prevent most cases of periodontal 
disease. 
1.1.d. Pathogenesis: Inflammation 
 Unfortunately for some patients, the discussion of prevention is too little too late, 
and calculus has been present long enough to elicit an immune response. The human 
body has two main pathways by which it fights off damaging insults: innate and adaptive 
immunity. Innate immunity innate immune cells such as macrophages and neutrophils 
detect evolutionarily conserved molecular patterns shared by all pathogens and mount a 
non-specific immune response.30 On the other hand, adaptive immune cells such as T and 
B lymphocytes have receptors specific to a single pathogen and mount a memory-based 
immune response.30 Periodontal disease develops through activation of both innate and 
adaptive immunity. The focus of this dissertation is on the innate immune response, and 
more specifically on macrophages, which have the capability to phagocytose pathogens 
process their antigens and signal to other immune cells through antigen presentation as 
well as secretion of cytokines and chemokines.30 When calculus is present on the surface 
of the tooth, macrophages that continually sample their environment commonly find 
danger associated molecular patterns (DAMPs) that are secreted by damaged or dying 




bacteria housed by the calculus mass have lipopolysaccharide (LPS) on their cell surface 
which is made pathogenic by the carbohydrate or O-antigen portion of its structure.  LPS 
can act as a pathogen associated molecular pattern (PAMP) and directly activate 
macrophages through binding to a specific pattern recognition receptor (PRR) on their cell 
surface. These receptors are called Toll-like receptors (TLR) and of the 11 classes found 
in humans, TLR-4 is specifically activated by periopathogenic LPS.  
Activation of these TLRs results in signaling through the cell in a well-studied 
inflammatory cascade. This signaling ultimately results in activation of nuclear factor 
kappa beta (NF-κB), a transcription factor responsible for creation of inflammatory 
cytokines such as IL-1β, IL-6 and TNF-α. First, TLR-4 activation is initiated through 
homodimerization following complex assembly with LPS, CD14 as a co-receptor, MD-2 
as an adapter, and LPS-binding protein as a cofactor.33 Following successful binding of 
LPS, TLR-4 signals to either myeloid differentiation factor 88 (MyD88) or toll/interferon 
receptor domain containing adapter-inducing interferon B (TRIF) and these are named 
the MyD88 dependent and independent pathways, respectively.34 In the MyD88 
dependent pathway, another split in the pathway occurs where either IκB kinase (IKK) 
activates NF-κb or mitogen-activated protein kinases (MAPKs) activate activating protein 
1 (AP-1). Both NF-κb and AP-1 are transcription factors that produce IL-6, IL-1b and TNF-
a. In the MyD88 independent pathway, IFN-β is produced through activation of Interferon 




(TANK)-binding kinase 1 and IKKs.35 Several of these cytokines can reliably be found in 
the gingival crevicular fluid of periodontally diseased hosts,36 and the use of these 
cytokines as a biomarker has been under investigation for several decades.37 These pro-
inflammatory cytokines initiate signaling cascades to attempt to re-establish periodontal 
homeostasis.38 Unfortunately, calculus is a fortified mass that is largely impenetrable by 
these forces while the host tissues, on the other hand, are highly susceptible to damage. 
In a perfect world, the immune response would be able to clear the calculus and spare 
 
Figure 1.1. Inflammatory cascade initiated by bacterial lipopolysaccharide resulting in production of pro-




the host of any damage. In reality, the opposite happens: host tissues suffer while the 
calculus and bacteria it houses thrive even more. (Figure 1.1) 
Interestingly, macrophages play a dual role in periodontal disease depending on 
how polarized they are towards inflammation or resolution. Classically activated or M1 
macrophages can secrete pro-inflammatory cytokines to recruit additional immune cells 
to the site. These macrophages are activated by exposure to lipopolysaccharide or IFN-
γ. On the other hand, pro-resolving macrophages or M2 macrophages have more anti-
inflammatory capabilities.39 M2 macrophages can be further broken down into M2a, M2b, 
or M2c depending on their specific activating factors.40 In periodontal disease, there is an 
imbalance in the M1/M2 ratio, where M1 macrophages predominate for the purpose of 
clearing microbes. This imbalance leads to tissue destruction characteristic of periodontal 
disease.41 Many studies have been conducted to understand the dynamics that govern 
polarization of macrophages towards one subset or another, as tight control of these 
processes could prove useful therapeutically. For example, KDM4D knockdown in 
fibroblasts results in IL-12 gene repression.42 IL-12 is associated with M1/Th1 immunity, 
as opposed to IL-10 which would drive the immune system towards M2/Th2 immunity.43  
Additionally, JMJD3 has been shown to be induced by LPS stimulation in macrophages.44 
This epigenetic enzyme demethylates H3K27me3 to H3K27me and its activity is critical 
for macrophage polarization into the M2 or anti-inflammatory state.45  The 
KDM4B/KDM1A axis is likely involved in this process heavily, as previous literature has 
shown that inhibition of the KDM4 family induces apoptosis in M1 macrophages and 
conversely introduction of a KDM1A inhibitor promotes expression of M1 markers and 




 In addition to 
macrophages, 
there are several 
other important 
immune cells that 




1.2) Although it is 
impossible to 
detail every cell 
involved in 
addition to all of 
their diverse 
functions, a brief 
overview will be 
provided. Gingival 
epithelial cells are 
a primary barrier 
to bacterial 
invasion as they 
line the 
































































provide a mechanical barrier. Neutrophils, also known as polymorphonuclear cells or 
PMNs, are a hallmark of acute inflammation.48 They are recruited by IL-8, which is 
secreted by junctional epithelial cells following injury.49 Neutrophils secrete granules that 
are generally protective but when aberrantly released can cause tissue and extracellular 
matrix damage. Additionally, neutrophils are short lived and the accumulation of dead cells 
in the periodontal tissues leads to additional tissue damage.50 Dendritic cells (DCs) are 
professional antigen presenting cells that survey their environment and have the most 
potent T cell activating function of all cells in the body.51 Thus, DCs are a major connecting 
point between innate and adaptive immunity and have been shown to affect periodontal 
disease pathogenesis positively and negatively.52 In fact, dendritic cells can differentiate 
into bone-resorbing osteoclasts, causing bone loss directly.53 Additionally, adaptive 
immunity plays a role in periodontal disease pathogenesis. CD4+ T cells, also known as 
T helper cells, play a central role in immunity and have several subsets. For example, Th1 
and Th17 cells are pro-inflammatory and are directed toward intracellular pathogens and 
bacteria, respectively.54 Both of these cell types are positively correlated with chronic 
periodontitis in humans,55 and inhibition of differentiation of either cell type confers 
protection from destruction.56-57 Th17 cells are upregulated in response to microbial 
dysbiosis56 as well as mechanical damage,55 both of which have been thought to 
contribute to pathogenesis of PD. B cells, which produce antibodies, are another adaptive 
immune cell type involved in PD pathogenesis. While B cells produce antibodies to 
bacterial antigens, they are also able to promote destruction of host tissues through 
production of anti-self antibodies.58 In fact, B cell deficient mice do not develop bone loss 
following bacterial infection, suggesting a pathologic role of these cells likely through 




a role such as natural killer cells,60 endothelial cells,61 fibroblasts,62 myeloid derived 
suppressor cells63 and more, it is increasingly clear that pathogenesis of periodontal 
disease is a complex process that is difficult to accurately model by using a single cell type 
and this will continue to challenge the field for some time. 
1.1.e. Pathogenesis: Bacteria 
In 1998 Socransky et. al. proposed that there are five main complexes of bacterial 
species that colonize periodontally diseased sites.64 This study implicated the “red 
complex” of bacteria as being highly correlated to deep pocket depths and bleeding on 
probing.64 These pathogens include: Porphyromonas gingivalis, Treponema denticola, 
and Tannerella forsythia.64 More recently, Hajishengallis et. al. proposed the “keystone 
pathogen hypothesis” which suggests that single, lowly abundant microorganisms lead 
to a dysbiotic periodontal microenvironment.65 This study suggested that Porphyromonas 
gingivalis was a keystone pathogen that if targeted individually, could result in resolution 
of inflammatory periodontal damage by stabilizing the dysbiotic microbial community.65 
More recently it was discovered that this model was oversimplified, and periodontal 
disease was dependent on a complex process leading to dysbiosis and altered overall 
subgingival flora rather than the mere presence of one or more specific periopathogens.66 
This model, termed the polymicrobial synergy and dysbiosis (PSD) model, considers that 
the polymicrobial biofilm is interdependent and pathogenic as a system rather than singly 
dependent on a keystone or red complex pathogen.66 Further studies have identified 
individual species related to specific disease subsets, such as Aggregatibacter 
actinomycetemcomitans (A.a), which has been uniquely associated with aggressive and 




the presence of specific pathogens as a screening device for progressive versus non-
progressive lesions or for classification of periodontal diseases,15 we have used this 
information to enhance our understanding of the biologic mechanisms at play and 
augment our in vitro and in vivo experimental models by using the bacteria that are most 
commonly associated with the disease to better replicate the disease process. 
 
1.1.f. Pathogenesis: Bone Loss 
A critical hallmark of periodontal damage is alveolar bone loss. Bone resorption is 
mediated by osteoclasts (OCs), while bone formation is mediated by osteoblasts (OBs). 
Under normal homeostatic balance, OBs and OCs constantly signal to each other to 
maintain a constant level of bone turnover. More specifically, osteoblasts produce 
receptor activator of nuclear factor kappa b ligand (RANK-L), which is a critical activator 
of osteoclasts. On the other hand, osteoblasts also secrete osteoprotegerin (OPG), which 
can inhibit the RANK-L signal by irreversibly binding to its receptor.68 In periodontal 
disease, there is imbalance in this process, and a net catabolic effect occurs by an 
increased osteoclast to osteoblast activity ratio.69 In fact, osteoclast formation can be 
induced by pro-inflammatory cytokines secreted by both innate and adaptive immune 
cells, such as TNF-α and IL-1.70 These same cytokines have been shown to deactivate 
osteoblasts, directly linking inflammation to the osteoblast-osteoclast activity ratio.69 
Additionally, macrophage colony stimulating factor (M-CSF) is a pro-inflammatory 
cytokine critical for the activation of both macrophages and osteoclasts,71-72 that is 
secreted primarily by osteoblasts in response to pro-inflammatory signals.73 This results 




in inflammatory-driven bone loss. Thus, in hyper-inflammatory conditions, osteoclast 
actions are heightened more than osteoblast actions, resulting in a net loss of bone. 
(Figure 2) 
1.1.h. Treatment Modalities 
Current and traditional therapy to treat periodontal disease includes scaling and 
root planing (SRP).74 Scaling involves mechanical debridement of plaque biofilms and 
calculus from clinical crowns using scalers, and root planing requires access to the root 
surfaces using surgical and non-surgical measures for the same purpose.75 This 
treatment has undergone continual refinement to involve an extensive array of 
instruments including ultrasonic scalers, which use ultrasonic energy to assist in removal 
of biofilms,76 although the foundational technique and principles have not changed since 
its conception. The basic concept is that by disrupting plaque biofilms, the host immune 
system will discontinue its attack on this altered environment and the tissue inflammation 
and subsequent cellular damage will stop. Unfortunately, complete removal of the entirety 
of the plaque by clinicians is highly unlikely,77 and nevertheless there are some patients 
who recur after therapy76. In fact, in aggressive periodontitis (currently referred to as 
stage III.C periodontitis), clinical attachment loss occurs in patients with a very limited 
plaque load.78 Due to the limited ability of SRP to completely heal the entire periodontally 
diseased population, several adjunctive therapeutics have been developed over the 
years.  
Initially, extensive research was conducted testing the use of systemic 
antimicrobial therapy for treatment of periodontal disease. Over the years, several 




clindamycin, amoxicillin, metronidazole, tetracycline, doxycycline, minocycline, 
azithromycin and more.79-83 Considering that antibiotic overuse has led to a widespread 
issue with antimicrobial resistance,84-85 the marginal benefits have limited the use of 
systemic antibiotic use to severe cases of disease.86 Local antimicrobials have been 
shown to be less effective than systemic antimicrobials but nevertheless are still used 
clinically.87 For example, PerioChip® and Atridox® are both bioresorbable discs either 
loaded with chlorhexidine gluconate or doxycycline hyclate, respectively.88 Arestin® is 
minocycline hydrochloride loaded in extended release nanoparticles.89, Periogard® is a 
chlorhexidine mouth rinse formulation.90 Unfortunately, clinically relevant improvements 
are not generally produced by using these drugs, and they still carry unwanted side 
effects.91 Because of these factors, local antimicrobials are not currently considered 
standard of care treatment, although they are commonly implemented as a last resort for 
desperate and severe cases.92  
Because the host immune response is the source of tissue destruction in 
periodontal disease, extensive research has been conducted toward targeting the host 
immune response. Several groups have demonstrated that non-steroidal anti-
inflammatory drugs (NSAIDs) are efficacious in reducing periodontal destruction. For 
example, indomethacin and flurbiprofen have been shown effective in reducing 
periodontal destruction when given systemically in animals.93 Interestingly, even topical 
application of an NSAID can reduce the destructive effects of periodontal disease.94 
Unfortunately, some of these effects were marginally significant, and when taken into 
clinical trials, were unable to produce statistically significant increases in clinical 
attachment or bone regeneration.95 While NSAIDS are an obvious choice considering 




aggressive and destructive periodontal diseases,96 many cell types are at play and play 
a contributing role in the pathogenesis of the disease that are not directly involved in the 
COX pathway. Additionally, NSAIDs have consistent side effects and chronic use is 
generally contraindicated to prevent damage.97 Nevertheless, further exploration of 
treating periodontal disease with NSAIDs is ongoing and could produce exciting data in 
the future. Most recently, an innovative cyclic treatment schedule has been used, 
reducing bone loss and inflammation in a randomized controlled clinical trial.98 
In addition to NSAIDs as host modulation therapy, many studies have suggested 
that inhibition of matrix metalloproteinases (MMPs) represent a promising therapeutic 
strategy for treating periodontal disease. MMPs are enzymes mainly secreted by 
fibroblasts that are responsible for maintenance of tissues through breakdown of 
extracellular matrix components.99 There are 23 different MMPs, all of which are 
endogenously inhibited by tissue inhibitors of MMPs (TIMPs).100 MMP-2, -8, -9 and -13 
are commonly studied with respect to periodontal disease because they are increased in 
either the gingival crevicular fluid or gingival tissues of periodontally diseased 
individuals.99 In periodontal disease, the MMP/TIMP ratio is increased resulting in a net 
breakdown of tissues.101 Although doxycycline was originally designed as a semi-
synthetic tetracycline, at sub-antimicrobial doses this compound has been shown to 
inhibit matrix metalloproteinases -8 and -13, and therefore has been marketed for 
treatment of periodontal disease as a host modulation therapy under the trade name 
Periostat®.102 Minocycline is another tetracycline analogue103 that has been evaluated as 
an MMP inhibitor in several diseases such as multiple sclerosis, vascular neurological 
disorders as well as periodontal disease.104 Small molecule MMP inhibitors have also 




monoclonal antibodies to MMPs have been developed and are currently being evaluated 
for treatment of tumor metastases.106-107 These antibodies will likely be evaluated for host 
modulation therapy for periodontal disease in the near future. 
Bisphosphonates (BPs) present an additional potential therapeutic class that could 
help mediate periodontal health in the over-inflamed host. BPs are pyrophosphate 
analogues that adsorb selectively to hydroxyapatite surfaces in bone and prevent 
breakdown of bone tissue through multiple independent mechanisms.108 In short, BPs 
inhibit osteoclast function and recruitment, leading to a reduction in alveolar bone loss.109 
Thus, these compounds have been implicated in diseases where bone loss is a clinical 
issue such as osteoporosis,110 osteogenesis imperfecta111 and periodontal disease.112 
Bisphosphonates have even been shown to exhibit anti-tumor activity through decreasing 
production of VEGF, inhibiting cellular proliferation and causing cell cycle arrest.113 
Unfortunately, osteonecrosis of the jaw (ONJ) is a common adverse outcome associated 
with bisphosphonate use. First described in 2003,114 bisphosphonate related 
osteonecrosis of the jaw (BRONJ) is an area of uncovered bone persisting for at least 8 
weeks in the maxillary and mandibular bones. The pathophysiology of the disease is 
poorly understood but several theories have been proposed115 including avascular 
necrosis, drug toxicity, reduced bone turnover due to compromised osteoclast-osteoblast 
interactions as well as inflammation such as is seen in periodontal disease.116 More 
recently, ONJ has been linked to the usage of anti-resorptive medications other than just 
bisphosphonates and thus has been renamed medication related osteonecrosis of the 
jaw (MRONJ).117 Second to BPs, ONJ is commonly seen in patients taking denosumab, 
a monoclonal antibody targeting RANK-L.118 While several additional medications have 




correlated with disease development.120-122 Considering these facts, the potential use of 
an anti-resorptive medications to treat periodontal bone loss has been employed with 
extreme caution.  
Based on the data presented above, there is an urgent need for development of 
novel treatment strategies for periodontal disease. The ideal agent would be a small 
molecule that could be applied topically, would interrupt the pathways that activate the 
inflammatory response, and prevent bone loss. This dissertation will describe our 
attempts to develop such an agent through structure-based design and structural 
optimization of potential lead compounds. 
1.2. Epigenetics 
1.2.a. Introduction 
The term epigenetics refers to reversible and heritable changes in the expression 
of DNA that do not involve changes in the primary DNA sequence. Over the last decade, 
there has been a dramatic increase in the study of epigenetic control mechanisms that 
play a role in the development of cancer and other diseases. The first epigenetic targeting 
therapeutic was technically FDA approved in 1968, but the fact that this drug, 5-
azacytidine, acted through an epigenetic mechanism was only discovered in 2004.123 In 
that same year, the first reversible histone demethylase enzyme, KDM1A, was 
discovered.124  Since then, a plethora of additional epigenetic modifying enzymes have 
been discovered, and various epigenetic mechanisms have been targeted for treatment 
of various diseases.  
Epigenetics contrasts with genetics, the study of inherited DNA alterations, 




expression of specific genes. Epigenetic changes are generally initiated in response to 
internal and external stimuli, and these processes are mediated through several different 
mechanisms within a cell. There are two basic mechanisms for the epigenetic control of 
gene expression: methylation of DNA at CpG islands in promoter regions of DNA and 
post-translational modification of histone proteins. The focus of this dissertation is on 
histone methylation/demethylation, specifically the demethylation activity of KDM4B and 
to a lesser extent KDM1A. This section will explore the general concepts of epigenetics, 
the mechanism of KDM4Bs enzymatic activity, some of the effects of that activity and 
finally how and why KDM4B has been targeted for drug development.  
1.2.b. Histone Modifications 
DNA is organized into tightly wound chromatin so that it can fit into the nucleus of 
a cell. Chromatin can either be relaxed euchromatin or condensed heterochromatin, 
depending on how tightly DNA is bound around nucleosomes, and this alters the 
accessibility of transcriptional machinery for purposes of replicating and expressing these 
genes. Nucleosomes consist of histones H1, H2A, H2B, H3 and H4, each of which has 
amino-terminal tails that are accessible for modification. (Figure 1.3) Histone methylation 
and acetylation are widely studied, while phosphorylation, ubiquitination, sumoylation and 
citrullination of histone tails have been less well characterized. These groups are generally 
transferred to very specific histone tails by “writers” and to be removed require an entirely 
separate set of very specific enzymes called “erasers”. For example, histone 
methyltransferase G9a is a writer capable of specifically transferring methyl groups to 
histone 3 lysine 9 (H3K9) and is only active in converting the mono-methylated form into 




eraser: histone demethylase KDM4B. To add to the complexity, the specificity of these 
enzymes is not always overlapping, as KDM4B has additional activity on the trimethyl state 
of histone 3 lysine 36 (H3K36me3) non-concurrent with G9a’s additional activity on 
H3K27. Once specific tails are modified, the modifications are read by yet another set of 
enzymes called readers, which are most commonly bromodomains. (Figure 1.4) In cancer 
and other diseases, DNA promoter hypermethylation in combination with abnormal 
histone modifications have been associated with the aberrant silencing of genes.126-128 
Epigenetic gene silencing, in combination with gene mutations, are critical mechanisms 
involved in the etiology and progression of virtually all cancers.126 Aberrant regulation of 
these processes can lead to silencing of tumor suppressor genes important in the 
development of cancer, and thus multiple chromatin remodeling enzymes have been 
targeted for the discovery of novel antitumor agents.129-131 More recently, dysregulated 
epigenetic modulation has been shown to be a factor in diseases other than cancer.  The 
focus of this dissertation is the histone demethylase enzyme class and its relation to the 
immune response in periodontal disease. The histone demethylases can be further broken 
down into FAD dependent (KDM1) and independent enzymes (KDM2-6). The FAD-
independent histone demethylases have a jumonji C domain responsible for their catalytic 
activity whereas the FAD-dependent use FAD as a cofactor and commonly form 
complexes to enhance their catalytic activity.132 
1.2.c. KDM1A 
The first discovered and most extensively studied FAD-dependent histone 
demethylase enzyme is KDM1A, also known as lysine-specific demethylase 1 (LSD1) The 




histone 3 lysine 4 (H3K4). KDM1A is specific for the substrates monomethyl histone 3 
lysine 4 (H3K4me) and dimethyl histone 3 lysine 4 (H3K4me2). H3K4 methylation states 
are generally correlated with active transcription, where higher methylation (trimethylation) 
is found on highly active genes.133 KDM1A is also known to demethylate histone 3 lysine 
9 (H3K9) when co-localized with the androgen receptor in prostate tumors,134 and also 
has  
non-histone protein substrates such as p53 and deoxynucleic acid  methyltransferase 1  
(Dnmt1).135 A number of effective KDM1A inhibitors have been identified, and include 
tranylcypromine-based irreversible inhibitors such as GSK2879552136 and ORY-1001,137-
139 oligoamines such as verlindamycin140 and related isosteric ureas and thioureas,141-142 
reversible benzohydrazide inhibitors such as SP-2509,139 reversible 1,2,4-triazoles,143 and 
dithiocarbamate-urea hybrid KDM1A inactivators.144 KDM1A is now regarded as an 
emerging drug target for diseases other than cancer, such as neurological disease,145-146 
blood disorders,147-148 viral infection,149 diabetes150-151 and fibrosis.152. The primary process 
KDM1A controls is cell proliferation and cell cycle regulation, and thus it has primarily been 
studied as a regulator in cancer cell progression and growth. It is clear that while KDM1A 
has several important regulatory functions, the potential of targeting this enzyme for 
treating human disease is in its infancy, and as time progresses it is certain that there will 
be development of further uses of inhibiting KDM1A as well as more and more potent 
KDM1A inhibitors.  
Relevant to the current discussion, KDM1A has more recently been linked to the 
host immune response. For example, KDM1A expression is reduced upon TLR activation 




hyperinflammation ensues causing host damage.153 Also, KDM1A is critical for activation 
 
Figure 1.3. Modifiable sites on histones. 
 




of B cells, and when KDM1A is ablated in these cells, immune response genes are 
overactivated.154 Agonizing histone demethylases is very difficult, and since the activity of 
KDM1A is correlated with immune suppression, we sought to determine a druggable target 
that would keep KDM1A active. More recently, Boulding et. Al showed that introduction of 
a KDM1A inhibitor promotes expression of M1 markers and decreases M2 markers.46 
 
1.2.d. KDM4B: Introduction 
The KDM4 family of epigenetic modifiers target the demethylation of histone 3 
lysine 9 and 36, as well as histone1.4 lysine 26. Each member contains a jumonji C (jmjC) 
domain responsible for the demethylation activity, and uses Fe2+, 2-oxoglutarate and O2 
for this activity.155 (Figure 1.5) Only family members KDM4A-C contain double PHD and 
Tudor domains, and these differences are thought to attribute to the variable specificity 
between A-C compared to isozymes D-F. KDM4A-C have a 5-fold specificity for H3K9 
over that of H3K36 and H1.4K26. KDM4B exhibits the lowest rate of demethylation within 
the family, for reasons that are not clear. KDM4D-F are half the size of other family 
members and are unable to demethylate H3K36.156 As shown above, demethylation of 
histone lysines occurs through a well-defined mechanism that is conserved among 
enzyme superfamily. First, ferrous iron binds to the active site by coordinating with one 
aspartic/glutamic acid and two histidines as well as water. 2-oxoglutarate (2-OG) then 
binds displacing some water, followed by binding of the histone lysine which displaces the 
remaining water that is bound to iron. This activates iron to undergo an oxidative 




the histone lysine, producing formaldehyde through a hemiaminal intermediate. The 2-OG  
 




is converted to succinate through this process and once it is released, ferrous iron is 
regenerated, allowing for further demethylation.132 
Trimethylation of H3K9 and H1.4K26 are classically thought to be repressive 
heterochromatin marks. This contrasts with H3K36 methylation which generally correlates 
with active expression.156 The mechanisms underlying various histone methylation 
patterns and the enzymes involved in repressing or activating genes are yet to be 
understood, but there is substantial evidence supporting the idea that histone modifying 
enzymes exhibit crosstalk behavior, and also influence DNA methylation activity. 
Additionally, the activity of an epigenetic enzyme can have an influence on more than just 
histone lysines. These enzymes have been implicated in processes such as cytosolic and 
nuclear protein modifications, alternative splicing, as well as recruitment of other proteins 
for complex formation.  
1.2.e. KDM4B: Immune Response 
KDM4B and its primary substrate, histone 3 lysine 9 (H3K9), have been implicated 
in numerous immunological processes. For example, trimethylation at H3K9 has been 
shown to contribute to the repression of TLR4 expression.157 In addition, TNFα 
transcription is repressed through H3K9 methylation during the process of endotoxin 
tolerance.158 Also, H3K9me3 levels are decreased in macrophages through exposure to 
high glucose, accompanied by a simultaneous increase in inflammatory cytokine 
production.159 H3K9me3 levels are also found to be increased in response to hypoxia, 
which downregulates mRNA expression of the chemokine Ccl2 and the chemokine 
receptors Ccr1 and Ccr5.160 Additionally, decreased levels of H3K9me3 is associated with 




of NF-κB p65 to their proximal promoters.161 Dulal Das et al reports that KDM4B 
knockdown recruits repressive methylation marks to the promoters of IL-1β and IL-2 genes 
among others in neural stem cells.162 IL-1β is an extremely important cytokine in the 
regulation of periodontal disease pathogenesis, and its transcription is prolonged by the 
bacterial challenge present in the plaque of diseased patients.163 KDM4B has also been 
shown to promote osteogenic over adipogenic differentiation of mesenchymal stem 
cells.164 Helicobacter pylori is the major etiological factor for development of gastric 
cancer, and a recent study found that H. pylori induces KDM4B overexpression in gastric 
tissues. The chronic inflammation seen in these tissues that leads from gastritis to gastric 
cancer is through NF-κB and COX-2, and this action is directly dependent on KDM4B 
demethylation activity.165 Although this data supports the idea that KDM4B activity is 
correlated to hyper-inflammation, further studies are needed to fully define the 
immunomodulatory mechanism of KDM4B in the context of periodontal disease.  
The KDM4 family is said to be able to demethylate H3K23me3, an underexplored 
chromatin mark. This allows for H3K36 demethylation activity to occur, which is an 
important epigenetic control point for meiosis and spermatogenesis. In relation to 
immunity, H3K36me2 expression results in expression of genes that promote plasma cell 
transformation.166 H3K36 methylation has also been associated with macrophage 
polarization, and increased methylation at this mark results in suppressed production of 
IL-6 and TNF-α by macrophages.167 
In addition to the traditional epigenetic mechanisms at play, KDM4B may 
functionally be linked to the immune response through immunometabolism. KDM4B is a 




dependent transcription is induced upon lipopolysaccharide pro-inflammatory stimulus 
and results in an increased glycolytic metabolic program in macrophages.169 The M1 
macrophage is a major immune cell responsible for inflammation. The expression of 
isocitrate dehydrogenase is decreased 7-fold in M1 macrophages compared to M0 
macrophages.170 This is the enzyme that converts citrate to alpha ketoglutarate (α-KG, 
also known as 2-oxoglutarate, 2-OG), which is a cofactor for KDM4 family of enzymes. In 
addition, α-KG is a source of glutamine and glutamate, and therefore plays a role in 
immunity through increases in immune cells and their respective activity.171 If less α-KG is 
available to contribute to these protective immune responses secondary to depletion by 
KDM4, it can be said that KDM4 contributes to the loss of the protective immune response 
provided by glutamine and glutamate through competition for α-KG.  
1.2.f. KDM4B: Drug Discovery 
The focus of epigenetic-based drug discovery research has been mainly directed 
towards histone deacetylases (HDACs) in the treatment of various cancers. More recently, 
the KDM4 family of epigenetic modifying enzymes have been found to be linked to positive 
regulation of many immunological processes, and therefore serve as an interesting target 
for development of hyperinflammatory or autoimmune disorders. Unfortunately, drug 
development in the realm of immunity has not been initiated, though development of 
KDM4 inhibitors for treatment of prostate and breast cancer continue to progress. The first 
series of inhibitors of the KDM4 family were based on 2-oxoglutarate (2-OG) 1 because 
of it’s critical role in the catalytic activity of the enzyme. N-oxalylglycine (NOG) 2 and 2-4-
pyridine dicarboxylic acid (2-4-PDCA) 3 have been shown to inhibit various KDM4 family 




unrelated enzymes.172 JIB-04 4 was the first KDM4 inhibitor that was not a 2-OG 
competitive inhibitor, and although it is a pan JmjC KDM inhibitor, it has no activity toward 
KDM1A or other epigenetic enzymes, proving useful for mechanistic studies.173 More 
recently, the 8-hydroxyquinoline (8-HQ) scaffold was identified as a hit through high-
throughput screening.174 These studies identified IOX1 5 as a potent KDM4 inhibitor but 
this drug has poor cell permeability and has to be used as a prodrug methyl ester.175 Based 
on this scaffold, several groups developed successful drugs, including the NIH Molecular 
Libraries program, which developed an extremely potent inhibitor, ML324 6.176 Selective 
targeting of specific KDM4 family enzymes has yet to be successful, and the structure 
activity relationships that govern selective binding are yet to be understood. Additional 
analogues of ML324 were developed that have variable selectivity within the KDM4 
family.177 Other groups have identified additional compounds able to inhibit the KDM4 
family such as NSC636819 7, a dinitrobenzene,178 circuminoids,179 pyridinyl thiazoles180 
and others, highlighting the diversity in available inhibitors and consequently the infancy 
in which KDM4 drug discovery exists. Studies describing development of KDM4 inhibitors 
rarely test the compounds for all of the KDM4 family members, and none have evaluated 
their inhibitors in both male and female samples, despite the association of these enzymes 
with sex-specific hormonal signaling pathways.181-182 (Figure 1.5) 




As new epigenetic enzymes are discovered that possess different targets for 








marks, will be 
attempted. It has 
been known for some time that epigenetic enzymes themselves can be epigenetically 
modified, which suggests a checks and balance system or a compensatory mechanism 
by which our cells can maintain homeostasis. On the other hand, when epigenetically-
controlled cellular processes are dysregulated to a degree that is beyond repair, small 
molecule therapeutics may be indicated to revert cells into a homeostatic state. 
Uncovering the entirety of this landscape will allow for understanding of how the histone 
modification system within our cells is responsible for making the changes necessary to 
drive an undifferentiated stem cell into a fully differentiated state. 
Histone demethylase enzymes conserved among diverse species, but these 
enzymes are commonly redundant, sharing substrate specificity among different classes 
and families, as well as coordinated in their activity. For example, the demethylation 
activity of KDM1A on H3K4 leads to repression of pro-inflammatory cytokine gene 
 
Figure 1.6. Compounds known to interact with KDM4B. Compounds 1-3 are 





transcription.183 Interestingly, previous data has shown that cross talk between KDM4B 
and KDM1A enzymes leads to a balanced system wherein lysine 9 methylation serves as 
a prerequisite to lysine 4 demethylation by KDM1A.184 In other words, when KDM4B is 
active at the H3K9me3 mark, KDM1A cannot be concurrently active at H3K4me2, and 
vice versa.184 KDM4B is then a positive regulator of the pro- inflammatory cytokine  
response through an indirect mechanism by inhibiting KDM1A. The link between these 
two histone marks is coupled to H3K9Ac levels, as has been additionally demonstrated in 
human CD4+ T cells. In this situation, T cell receptor stimulation induces pathologic FasL 
production proportional to the amount of H3K9 demethylation, H3K9 acetylation and H3K4 
methylation.185 Therefore, we are able to use coordination between mutually exclusive 
histone demethylases to antagonize one and indirectly agonize another. 
 
Figure 1.7. Proposed KDM4B-mediated immunomodulation mechanism. Coordination between KDM1A and 





1.3. Sex Differences  
It is well known that sex plays a key role in the acquisition and progression of 
immune diseases. More specifically for periodontal disease, 56% of men have the disease 
compared to only 38% of females. Furthermore, 16.5% of male patients manifest with 
severe disease compared to 7.6% of females.186 In general, females are thought to have 
superior functioning immune systems with responses more appropriate to clear the 
antigens and cause no further damage. For example, males are known to produce more 
damaging TNF-α in response to LPS, while females are known to be more efficient at 
antigen presentation. Additionally, circulating sex hormones may influence immune 
signaling, as there are estrogen and androgen response elements on the promoters of 
many acute inflammatory genes. Testosterone is generally immunosuppressive and is 
found in higher amounts in post-pubertal males than females. On the other hand, estrogen 
has an immune activating effect, increasing production of IL-1, IL-6 and TNF-α by 
macrophages.187  
KDM4B regulates sex hormone signaling events. Current literature suggests that 
KDM4B can modulate cell signaling during androgen receptor (AR) mediated cancer 
growth and suppression, suggesting that KDM4B inhibition affects androgen receptor 
signaling leading to cancer cell death. More specifically, Coffey et al concluded that AR is 
depleted in response to KDM4B knockdown, and in turn KDM4B is required for the 
transcriptional activity of AR.188 Additionally, while KDM1A is overexpressed in breast 
cancer and its activity upregulates ER transcription,189 KDM4B has been identified as an 
estrogen receptor co-regulator and its inhibition limits breast cancer growth via GATA-3 




estrogen dependent cell proliferation and growth.191 Despite these facts, ongoing research 
does not address the differential effects of sex on KDM4B signaling and immune 
processing. Wang et al. recently reported that KDM4A is required for M1 macrophage 
polarization in RAW264.7 macrophages, and that pharmacologic inhibition of the KDM4 
family induces apoptosis in these cells.47 Unfortunately, RAW264.7 macrophages are a 
male murine cancer cell line and therefore this data cannot be generalized to males and 
females. Additionally, Choi et al. demonstrated that ML324 treatment blocks TNF-α 
mediated neutrophil adhesion, a process critical for immune response propagation, but 
only conducted the experiment in male mice.192 Thus, in addition to the importance of 
studying sex differences in periodontal disease, KDM4B also likely has sexual dimorphic 
characteristics; therefore, the work presented in this dissertation has been done in both 
sexes wherever possible, to account for these potential factors.  
1.4. Systemic disease 
Periodontal disease has been linked to several systemic diseases, which may 
have an underlying epigenetic component driving their correlation.  One systemic disease 
which has been extensively linked to periodontal disease is diabetes mellitus (DM), a 
disease where the body’s insulin is improperly managed, resulting in excessive blood 
glucose levels. This link has been attributed to several factors, but the most prominent is 
that both PD and DM patients exhibit a hyper-inflammatory state. For example, diabetic 
and obese patients exhibit higher serum levels of IL-6 and TNFa.193 Additionally, diabetic 
patients have higher IL-1b and PGE2 in their gingival crevicular fluid.194 Interestingly, 
monocytes from diabetic patients exhibit a hyper-inflammatory state, secreting higher 




monocytes from non-diabetic individuals.195 KDM4B inhibition results in methylation of 
H3K9 and is required for deacetylation at H3 and H4.196 This switch from methylation to 
acetylation at H3K9 is activated by p38 MAPK, by phosphorylating lysine 
methyltransferase 1A (KMT1A) and disabling its interaction with target genes.197 P38 
MAPK has long been known to positively regulate the immune response, but only more 
recently has the role of H3K9ac been characterized as a contributor to this activity. 
H3K9ac is increased in macrophages from diabetic mice, and this mark drives 
STAT1/MyD88 expression and subsequent sterile inflammation found in diabetes.198 
following hyperglycemic treatment, expression of SUV39H1, one of the histone 
methyltransferases that acts on H3K9, is decreased. Alternatively, glucose treatment 
recruits KDM1A to the NF-κB p65 promoter, an observation that has previously been 
shown to induce inflammatory cytokine expression. Interestingly, hyperglycemia increases 
H3K4 methylation and decreases H3K9 methylation, a pattern consistent with what we 
believe initiates immune dysfunction seen in periodontal disease.199 These data suggest 
that the underlying link observed between diabetes and periodontal disease may be due 
to a dysregulated histone code, specifically involving KDM4B and KDM1A.  
In addition to diabetes, obesity has also been extensively linked to both periodontal 
disease as well as epigenetic modifications. Obesity increases a patients risk of both 
acquiring periodontal disease as well as more severe forms of the disease.200  For 
example, systemic inflammation and periodontal disease parameters such as probing 
depth induced by obesity can be decreased with dietary management.201 Additionally, oral 
administration of the periopathogen P. gingivalis has effects on the gut microbiota, which 




microbiome than that of their healthy counterparts, including significantly increased levels 
of the keystone pathogen genus prevotella.203 Simply feeding mice a high-fat diet results 
in alveolar bone loss and increased pro-inflammatory cytokine production as compared to 
feeding mice a normal diet.204 With regards to epigenetics, KDM4C is able to control 
adipogenesis via repression of PPAR-gamma, and has consequently been identified as a 
potential therapeutic for obesity or type 2 diabetes mellitus 205. KDM4B has also shown to 
promote osteogenic over adipogenic differentiation of mesenchymal stem cells. This 
potentially links the KDM4 family with both bone diseases as well as obesity 164. Not 
surprisingly, two back-to-back 2009 studies demonstrated that KDM4B knockout mice 
spontaneously develop obesity.206-207 When KDM4B is specifically knocked out in 
adipocytes, these cells exhibit decreased energy expenditure as well as decreased 
glucose and lipid metabolism.208-209 These data suggest that KDM4B may be dysregulated 
in both periodontal disease and obesity, but cell-type specific activity of this enzyme may 
be an important consideration for treatment of either disease. 
1.5. Rationale for dissertation 
Goals of the Proposed Research: Periodontal diseases (PD) affect 42% of the adult 
American population and are characterized by bacterial-driven inflammatory bone loss. 
Present adjunctive therapies to manage PD have limited clinical value, and in some cases 
carry potential side effects that may outweigh their benefit. It is well known that histone 
demethylases can modulate the immune response, but their correlation with periodontal 
status is largely unknown 155, 183-184, 210. The primary objective of this research is to define 
the epigenetic profile of periodontal disease, specifically in the context of histone 




with a greater ability to modulate PD pathogenesis through targeting inflammation and 
bone loss. 
1.5.a. Hypothesis. The demethylation activity of KDM1A on histone 3 lysine 4 results in 
a reduction of pro-inflammatory cytokine transcription 183. The histone lysine demethylase 
KDM4B is a histone demethylase that specifically demethylates histone 
3 trimethyllysine 9 (H3K9me3) 155, but this demethylation activity is mutually exclusive of 
demethylation of H3K4me2 by KDM1A 184. This proposal will take advantage of this 
coordination to reduce pro-inflammatory cytokine transcription by promoting 
KDM1A activity through KDM4B inhibition. The central hypothesis of this proposal is that 
promotion of KDM1A activity by introduction of a specific KDM4B inhibitor will alleviate PD 
inflammation and bone loss and that by controlling the overactive immune system in 
diseased areas, it will enable the host to better manage the disease and prevent its 
recurrence. We will test this hypothesis through completion of the following Specific Aims: 
1.5.b. Specific Aims 
1.5.b.1. Specific Aim 1:  We will define the role of KDM4B in periodontal inflammation 
and explore the mechanism by which these changes are mediated. KDM4B abundance 
will be assessed in perio-pathogen activated inflammatory bone loss tissue sections. In 
vitro, TNF-α and IL-6 response to A. actinomycetemcomitans LPS (Aa-LPS), a major 
immunodominate surface antigen of a common perio-pathogen will be measured following 
KDM4B inhibition with commercially available inhibitors. To further define the 
immunomodulatory role of KDM4B, osteoclastogenesis will be measured in the presence 




1.5.b.2. Specific Aim 2: We will use structure-based design techniques to discover novel 
inhibitors of KDM4B for adjunctive treatment of PD inflammation. We will dock compounds 
from large commercially available libraries to the crystal structure of KDM4B using a 
modification of previously described techniques.211-212 As hits are identified, 2D orthogonal 
mathematical models will be used to correlate immunomodulatory activity to structural 
characteristics of compounds. Immune modulation will be phenotypically screened using 
a primary macrophage model of PD. Top candidates will be synthesized and analyzed for 
cytotoxicity and immunomodulatory potential in vitro. For effective compounds, IC50 values 
will be determined. 
1.5.b.3. Specific Aim 3: We will evaluate novel and known KDM4B inhibitors for 
immunomodulatory activity in vivo. Promising KDM4B inhibitors, as well as the previously 
defined KDM4B inhibitor (ML324), will be evaluated in a murine calvarial inflammatory 
bone loss model of periodontal disease. Wild type C57BL/6 mice 12-14 weeks old will be 
injected subcutaneously with fixed A. actinomycetemcomitans following pre-treatment 
with drug or vehicle control in the mid-sagittal region of the calvarium every day for 5 days 
to induce inflammatory bone loss. Compounds will be evaluated over a 100-fold 
concentration range as defined by maximum tolerated dose, and bone loss will be 
evaluated by micro-computed tomography. Tissues overlying the calvarial bones will be 
analyzed for changes in histone methylation marks.  
1.5.c. Impact on the Field.  The proposed research will elucidate an underlying epigenetic 
mechanism of PD pathogenesis and validate KDM4B as a drug target, thereby opening 
new doors for drug development and allowing for an enhanced understanding of the inter-




the development of a novel immunomodulatory compounds, which could be used in future 
periodontal disease studies.  
 
Chapter 2: Materials/Methods 
2.1. Animal Care and Use 
C57BL/6 mice were purchased from Jackson Laboratories and maintained in accordance 
with NIH guidelines. Animals subject to food and tap water ad libitum and maintained 
under normal 12-hour light cycles. Animals were euthanized via CO2 asphyxiation and 
death verified by cervical dislocation. Experimental protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) at the Medical University of South 
Carolina under protocol number #2718. 
2.2 Bacterial culture 
Aggregatibacter actinomycetemcomitans strain Y4 was purchased from American Type 
Culture Collection (ATCC) and grown following manufacturer’s protocols. A single colony 
was selected by plating the bacterial suspension onto brain heart infusion (BHI) agar and 
incubating for 3 days in a 5% CO2 incubator at 34 °C. A single colony was picked and 
expanded in 10mL BHI broth overnight on a shaker. A growth curve was generated by 
inoculating 10uL of this expanded solution into 20mL broth and monitoring the optical 
density at a wavelength of 450nm every hour. At the mid-logarithmic growth phase, 
bacteria were quantified using serial dilutions. Bacteria were expanded into 500mL and 
diluted to OD450 = 0.3. Bacteria were centrifuged at 1500 x g for 10 minutes, washed with 




removed by pelleting the fixed bacteria at 1500 x g and rinsing twice with PBS. Bacteria 
were resuspended in PBS for in vitro experimentation and calvarial injections. 
2.3 Murine Calvarial Model 
Mice were anesthetized using isoflurane inhalation where fifteen uL of 12.5 or 20 μM of 
ML324, 20 μM 36 or DMSO vehicle control in a 15 μL volume. One hour later, mice were 
anesthetized using isoflurane and 2x109 CFU fixed Aggregatibacter 
actinomycetemcoitans strain Y4, serotype b or phosphate buffered saline (PBS) vehicle 
control was injected subcutaneously supraosteal to the mid-sagittal suture between the 
eyes and ears to approximate the bregma point into 12-week C57BL/6 male mice. 
Injections were repeated every 24 hours for 5 days. On day 6, 18 hours following the final 
 




injection, mice were euthanized and connective tissue and skin overlying the calvarial 
bone was flash frozen, ground using a mortar and pestle and resuspended in M-PER 
protein isolation buffer. Calvarial bones were fixed in 10% formalin for 24h and then stored 
in ethanol for micro-computed tomographic analysis.  
2.4 Protein Isolation and Immunoblotting 
Protein was isolated from skin and connective tissue overlying the calvarial bone by flash 
freezing tissues upon collection and immediately resuspending the ground tissues in 500 
μL of mammalian protein extraction reagent (M-PER, Thermo fisher). Solutions were 
sonicated at 4 ○C for 60 seconds and centrifuged at 1500 x g. Pellets were discarded and 
supernatant solution containing protein was analyzed using a BCA assay. 25ug protein 
was run on a SDS-PAGE gel along with Precision Plus Protein Dual Color standards (Bio-
Rad). Gels were transferred to a PVDF membrane using the trans-blot turbo transfer 
system (Bio-Rad) and blocked in 5% fat-free milk in TBS-T overnight at 4 ○C. Blots were 
incubated with primary antibodies in TBS-T overnight at 4 ○C. Blots were washed three 
times in TBS-T and were incubated for 1 hour at room temperature with secondary 
antibody in TBS-T. Blots were washed three times in TBS-T and developed using Azure 
Biosciences ECL reagent. Blots were imaged using the Azure c600 imaging system and 
densitometric analysis of protein was done using ImageJ software. Proteins of interest 
were normalized to GAPDH as a standard.  
2.5 mRNA isolation and qRT-PCR 
Media was rinsed with PBS and cells were lysed using TriZol Reagent (Invitrogen, 
Cat# 15596026). mRNA was isolated according to manufacturer’s protocols and purity 




reverse-transcription real time polymerase chain (qRT-PCR) reaction was run using a 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Cat# 4368814) 
followed by TaqMan® Fast Advanced Master Mix (Applied Biosystems, Cat# 4444557) 
with TaqMan® Gene Expression Assay Primers (Applied biosystems, listed below) using 
a StepOne Plus instrument (Thermo Fisher). TNF-α, IL-6 and the internal control GAPDH 
were then quantitated for each sample in triplicate. Results are reported as fold change 
(2-^^CT). 
2.6 Cell Culture 
All Cells were cultured at 37 ○C in 5% CO2. 
2.6.a. RAW264.7. Cells were cultured in dulbecco’s modified essential medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. (P/S) 
2.6.b. Primary Bone Marrow Macrophage Cell culture. Primary bone marrow was 
cultured into macrophages as described previously 213. Briefly, bone marrow from left and 
right femurs and tibiae of 12-14-week old wild type C57BL/6 mice was flushed into α-MEM 
(Corning, Cat# 10-022-CV) supplemented with 10% fetal bovine serum (Hyclone, Cat# 
SH30071.03HI) and 1% penicillin streptomycin (Sigma, Cat# P4333) and plated overnight 
at 37 °C in 5% CO2. Cells remaining in suspension were differentiated into experimental 
wells at a concentration of 2E6 cells/mL for 7 days or until 80% confluency and 
homogeneity was achieved using macrophage colony stimulating factor (R&D Systems, 
Cat# 416-ML-500), reconstituted in PBS + 1% BSA (Sigma, Cat# A8806) supplementation 





 BMDMs were pre-treated with experimental KDM4B inhibitors for 1 hour at various 
concentrations followed by incubation with Aggregatibacter actinomycetemcomitans 
lipopolysaccharide (A.a LPS) for various time points (generally 8, 16 or 24h). 
2.6.c. Primary Bone Marrow Osteoclast Cell culture. 
Bone marrow stem cells were isolated from C57BL/6 mice, and differentiated into 
osteoclasts as previously described 214-215. In brief, bone marrow isolated from femurs and 
tibiae of 12 week-old wild-type C57BL/6 mice was plated overnight into phenol red free α-
MEM (Gibco, Cat# 41061-029). Adherent cells were discarded and cells that remained in 
suspension were plated into the wells of a 96-well culture plate (Corning, Cat#3598) at a 
density of 15,000 cells/well. Cells were supplemented with macrophage colony stimulating 
factor (M-CSF, R&D Systems, Cat# 416-ML-500) (15ng/mL/48h) for 3 days followed by 
supplementing with M-CSF (15ng/mL/48h) and receptor activator of nuclear factor kappa 
b ligand (RANK-L) (R&D Systems, Cat# 462-TEC-010) (50ng/mL/48h) for 2 days. On day 
5, wells were rinsed to remove RANK-L and replacement media was supplemented with 
M-CSF (15ng/mL) with or without Aa-LPS (100ng/mL) or RANK-L (R&D Systems, Cat# 
462-TEC-010) (50ng/mL) and ML324 (SelleckChem, Cat# S7296, 10μM) or DMSO 
vehicle control for 72 hours.  
2.7. TRAP staining and enumeration 
Following osteoclast formation experiments, cells were rinsed twice, fixed with 10% 
glutaraldehyde (Fisher, Cat# O2957-1) and stained for tartrate resistant acid phosphatase 
(TRAP) as described in BD Bioscience Technical Bulletin No. 445 using a 10-minute 
incubation with TRAP buffer. Subsequently, 3 representative images per well were 




camera (Media Cybernetics). Osteoclasts were quantified as multinucleated, TRAP+ cells 
and statistically significant differences were computed using a paired one-way ANOVA 
with multiple comparisons with an alpha of 0.05. 
2.8. Cycloheximide Treatment 
RAW264.7 macrophages were grown to 80% confluence in α-MEM supplemented with 
10% FBS (Hyclone, Cat# SH30071.03HI) and 1% penicillin/streptomycin (Sigma, Cat# 
P4333). Cells were then pre-treated with ML324 (SelleckChem, Cat# S7296, 50μM) or 
DMSO vehicle control with or without cycloheximide (Sigma, Cat# C7698, 10μg/mL) for 
4h. DMSO remained constant in each group at a level of 0.1% to eliminate interference 
with the assay. Cells were challenged with A.a LPS (100 ng/mL) or PBS vehicle control 
for 24 hours and collected for qRT-PCR analysis. 
2.9. Immunofluorescence  
RAW264.7 macrophages were grown to 80% confluence in phenol red free α-MEM 
(Gibco, Cat# 41061-029) supplemented with 10% FBS (Hyclone, Cat# SH30071.03HI) 
and 1% penicillin/streptomycin (Sigma, Cat# P4333) on Sensoplate Plus glass bottom 
plates (Grenier Bio-One, Cat# 655892). Cells were pre-treated for 1 hour with test 
inhibitors (SelleckChem, Cat# S7296, 50 μM) or DMSO vehicle control followed by A.a 
LPS (100 ng/mL) for 24 hours. Cells were then rinsed with PBS and fixed using 4% 
paraformaldehyde (Sigma) at 37 °C for 10 minutes. Cells were permeablized using 0.1% 
Triton X-100 (Amresco, Cat# 0694) for 10 minutes and blocked using 3% Bovine Serum 
Albumin (Sigma, Cat# A8806) in PBS for 30 minutes. Cells were then incubated for 1 hour 
with rabbit anti-H3K4me (Active Motif, Cat# 39297, 1:750) in 3% BSA. Cells were rinsed 




in 3% serum for 1 hour. Cells were counterstained with DAPI (VWR, Cat# 95059-474, 
30μM) and AlexaFluor Phalloidin 488 (Invitrogen, A12379). Images were captured using 
a Wiscan imaging system (Hermes). 32-36 Images per well were used for analysis (n = 3 
wells/group). 
2.10. Human Periodontal Tissue Procurement 
This study was approved by the Institutional Review Board for the Health Sciences at the 
Medical University of South Carolina, USA.  Samples used for the present study represent 
a subset of samples used for a larger study. Informed consent was obtained with all 
patients prior to initiating study. Prior to surgery, clinical parameters were measured at the 
same sites where tissues were harvested including: plaque Index (PI) on a scale of 0-3 
(0-no plaque, 1-w/probe, 2-visible, 3-abundant) 216, gingival Index (GI) on a scale of 0-3 
(0-no inflammation, 1-mild, 2-moderate w/BOP, 3-severe, spontaneous bleeding on 
probing (BOP), pocket depth (PD), BOP, gingival recession (REC) and clinical attachment 
level (CAL).  Based on these parameters the inclusion criteria for the diseased group 
consisted of at least 1 site with PD>4mm, GI 1-3 and PI 1-3.  For the healthy controls 
acceptable parameters were: PD≤4mm, GI≤1, and PI≤2. The exclusion criteria for both 
groups included: smokers, unstable systemic diseases or chronic disorders (diabetes, 
rheumatoid arthritis), patients using steroids, antibiotics, NSAIDS and/or other host 
modulators. The procured samples were from tissues that would have been otherwise 
discarded after periodontal surgery and or extraction sites.  When clinically indicated, 







Calvariae from mice with periodontal disease, collected as previously described 217 were 
formalin fixed, decalcified using 0.5 M EDTA, pH 8.0 for 2 weeks, paraffin embedded and 
cut into 7 μm sections following standard protocols. Human periodontal tissues were 
formalin fixed, paraffin embedded and cut into 7 μm sections following standard protocols. 
Sections were permeablized using 0.2 M boric acid (Sigma, Cat# B6768). Tartrate 
resistant acid phosphatase (TRAP) was measured as described in BD Bioscience 
Technical Bulletin No. 445 following a 30-minute incubation with TRAP buffer. KDM4B 
was visualized following blocking with 3% normal goat serum (SeraCare, Cat# 5560-0007) 
using rabbit anti-KDM4B (AbCam, Cat# ab191434, 1:125) or rabbit anti-KDM4E (Novus, 
Cat# NBP2-49124) overnight at 4°C. The sample was then incubated for 1 hour with 
biotinylated goat anti-rabbit (Vectorlabs, Cat# BA-1000, 1:500). VECTASTAIN Elite ABC 
HRP Kit (Vectorlabs, 1:500, Cat# PK-6100), and a DAB Peroxidase (HRP) Substrate Kit 
(Vectorlabs, Cat# SK-4100) was then used for development. 15% Hematoxylin (Sigma, 
Cat# H3136) was employed as a counterstain. Images were captured using a Nikon 80i 
Eclipse microscope equipped with a DS-Fi1 camera. Region of interest selection and 
subsequent quantification was performed using visiopharm software (n = 3) for calvarial 
tissues. Human periodontal tissues were analyzed using imagej (n = 5-9). 
2.12. JMJD2B Enzyme Assay 
Inhibition of JMJD2B was assayed by BPS Biosciences using an 11-point IC50 
determination using the histone demethylase AlphaScreen (PerkinElmer) assay (BPS 
Bioscience, Cat# 50414). Briefly, enzymatic reactions were conducted in triplicate at room 




Cat# 52407), histone H3 peptide substrate, demethylase enzyme (BPS Bioscience, Cat# 
50111), and ML324 or 2,4-pyridine dicarboxylic acid as a reference inhibitor. All wells had 
a final DMSO concentration of 1%. After the enzymatic reactions were complete, anti-
Mouse Acceptor beads (PerkinElmer, Cat# AL105C, 1:500) and Primary H3K9me3 
antibody (BPS Biosciences, Cat# 52140E, 1:200) were added and samples were mixed. 
The reactions were incubated for an additional 30 minutes followed by addition of 
AlphaScreen Streptavidin-conjugated donor beads (PerkinElmer,Cat# 6760002S, 1:125). 
30 minutes later the samples were measured using an AlphaScreen microplate reader 
(EnSpire Alpha 2390 Multilabel Reader, PerkinElmer). In the absence of the compound, 
the intensity (Ce) in each data set was defined as 100% activity. In the absence of enzyme, 
the intensity (C0) in each data set was defined as 0% activity. The percent activity in the 
presence of each compound was calculated according to the following equation: %activity 
= (C-C0)/(Ce-C0), where C is the A-screen intensity in the presence of the compound. A 
plot of % activity versus concentration was then constructed using non-linear regression 
analysis of the sigmoidal dose-response curve generated with the equation Y=B+(T-
B)/1+10((LogIC50-X)×Hill Slope), where Y is percent activity, B is the minimum percent activity, T 
is the maximum percent activity, X is the logarithm of compound concentration and Hill 
Slope is the slope factor/Hill coefficient. The IC50 value was determined as the 
concentration causing half-maximal percent activity. 
2.13. Enzyme-Linked Immunosorbent Assay (ELISA) 
Following cell culture experiments, supernatant proteins were collected for analysis by 
ELISA. Standardization of samples was based on cell count at the initiation of 




Samples were centrifuged at 1500 x g to remove insoluble contaminants. 96 well plates 
were coated with capture antibody overnight, washed three times and blocked with 1% 
BSA for 2 hours. After washing, samples were added to plates in a 100uL sample volume. 
Dilutions of samples were only done when necessary, in a subsequent assay if 
concentrations were not within the linear range of the standard curve. After a 2 hour 
incubation, plates were washed and a detection antibody was added and plates were 
incubated for 1 hour. Plates were washed and incubated with streptavidin:HRP for 20 
minutes. Plates were washed and developed using proprietary color reagents from R&D 
Biosystems. Development was stopped by the addition of 2N H2SO4 and plates were read 
using a Spectramax plate reader at 560nm. Plates were normalized to a blank well when 
possible. A standard curve was fit using a log-log algorithm within the spectramax software 
and concentrations were determined for each sample. Significance was determined using 
either One-way or Two-way ANOVA with multiple comparisons, when applicable. 
2.14. Micro-Computed Tomography 
Calvariae were dissected from surrounding tissues upon sacrifice and immediately 
submerged in 10% formalin for fixation. Bones were incubated overnight at room 
temperature on a shaker to ensure complete fixation. Solutions were replaced with 70% 
ethanol to rinse and then stored for long-term analysis in a fresh solution of 70% ethanol. 
Samples were sent to Maria Johnson at University of Alabama Birmingham for scanning. 
Scans were run on a Scanco 40 instrument at a 15 μm resolution. A cylindrical region of 
interest was selected centered around the bregma point and samples were thresholded 




determined using Analyze Pro software and statistical significance was determined using 
a Student’s t-test.  
 
2.15. Computational Chemistry 
2.15.a. Docking Experiments 
DOCK6.5: The KDM4B crystal structure (PDB: 4LXL) was prepared using UCSF Chimera 
following DOCK6.5 protocols.218 Ligands and water molecules were removed from the 
crystal structure. The ZINC15 compound database was filtered using pre-defined subsets 
of compounds: those with predicted in vitro activity in combination with compounds that 
were purchasable.219 This library was further refined by generating descriptors in 
Molecular Operating Environment (CGS) software in a high-throughput manner and 
eliminating large numbers of compounds based on these unfavorable descriptors: 
violation of one or more of Lipinski’s rules, molecular weight less than 250 and greater 
than 500 g/mol, greater than 12 rotatable bonds, compounds with a formal charge <-2 or 
>2 and the library was charged and energy pre-minimized for each structure based on 
standard protocols. The compound library was docked using DOCK6.5 in an unbiased 
manner by using the entire enzyme as the active site for docking in flexible mode with 
1000 maximum orientations per computation. The compound library was concurrently 
docked using Molecular Operating Environment in a rigid receptor dock constrained to the 
active site identified by the site finder tool in MOE. Hits from both programs were ranked 
based on the percentage of the maximum binding energy of each hit. Compounds that 
ranked independently within the top 70% of both docking experiments were selected for 




consensus hits using Chemmine cheminformatics online tools.220 Compounds were 
clustered by similarity and hits clustered in the smallest clade containing ML324, JIB-04 
and NSC636819 were selected for in vitro evaluation. This consensus docking strategy 
was performed on a combinatorial library of novel compounds as needed to prioritize 
synthetic efforts.  
2.15.b. Quantitative structure activity relationship (QSAR) development 
The phenotypic immunosuppressive screen data was converted into binary data using 
statistical significance (P<0.05) determined by One-Way ANOVA compared to DMSO 
controls as a cutoff. A contingency analysis was run on the tested compounds to identify 
the 2D descriptors defined by MOE that were most highly correlated with activity. The top 
12 descriptors from this analysis were used to map a quantitative structure activity 
relationship algorithm and cross-validation was conducted using a leave one out method 
following standard protocols. The model was applied to our combinatorial library to predict 
activity.221-222 
2.16. Synthetic Chemistry 
2.16.a. General Procedures: All solvents and chemicals were reagent grade. Anhydrous 
dichloromethane (DCM) and dichloroethane (DCE) were purchased from VWR. All 
solutions were dried over anhydrous magnesium sulfate or sodium sulfate, solvents were 
removed by rotary evaporation under reduced pressure. Solids used in dry reactions were 
additionally freeze dried before use. Microwave reactions were run in a Biotage Initiator. 
Flash column chromatography was carried out using pre-packed silica columns from 
RediSep or SiliCycle and mixtures adsorbed onto ISOLUTE for elution. Purity of 




spectra were recorded on a Bruker 400 MHz instrument using CDCl3, MeOD or DMSOd6 
as solvents. Chemical shifts are reported in ppm relative to TMS (0.00 ppm) or solvent 
peaks as an internal reference. Splitting patterns are indicated as follows: s, singlet; d, 
doublet; t, triplet; q, quartet; m, multiplet.  
All data are represented as geometric mean ± standard error of the mean (SEM) and 
statistical significance was determined using One-Way ANOVA with multiple comparisons 
(p<0.05). 
2.16.b. Compound 2: 5-Chloro-2-[(E)-2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-
yl]pyridine (JIB-04). Hydrazine hydrate (5.48 g, 171 mmol, 5.34 mL) was added to a 
solution of 2,5-dichloropyridine 1 (0.21 g, 1.42 mmol) in pyridine (10 mL) and the reaction 
mixture was refluxed for 6 h. The resulting suspension was dried in vacuo (rotary 
evaporator), dissolved in dichloromethane and washed with a 50 mL portion of 1.0 N 
NaOH and three 50 mL portions of water. The organic layer was dried over anhydrous 
magnesium sulfate, filtered, and the solvent was removed in vacuo to yield 5-chloro-2-
hydrazinylpyridine 2 as a white crystalline solid (0.097 g, 47%)  
A 20 mg portion of 2 (20 mg, 1.4 mmol) and benzoyl pyridine 3 (25.5 mg, 1.4 mmol) were 
refluxed overnight in methanol (10 mL) with a traces of acetic acid. The resulting solution 
was dried via rotary evaporator and crystallized from ethyl acetate to yield 5-Chloro-2-[(E)-
2-[phenyl(pyridin-2-yl)methylidene]hydrazin-1-yl]pyridine (JIB-04) 4 as fine yellow needles 
(0.099 g, 23%).  
2.16.c. Compound 16, 23-28: Biphenyl benzoyl chloride (3.6 mmol) was added to 
aminobenzoate derivatives 17 (3 mmol) under reflux in toluene (25 mL) as previously 




pressure by adding water continually until all toluene was removed. Product was extracted 
from ethyl acetate rinsing with brine. The remaining organic layer was loaded onto a 25g 
silica column and purified using flash chromatography with a solvent gradient from 0-100% 
ethyl acetate in hexanes over 25 minutes. Fractions containing product 18 were combined 
and identity of products were confirmed using UPLC and NMR. 
The resulting ester 18 (1 mmol) was added to a microwave vial with LiOH (.5 mmol) and 
dissolved in methanol and water (3:1, 10mL). The reaction was microwave irradiated at 
100 ○C for 1-2 hours until the ester starting material was consumed. The reaction was 
acidified, evaporated under reduced pressure, and vacuum filtered rinsing with cold HCl 
to yield product 16, 23-28 as a white to off-white solid. 
Final products were lyophilized and analyzed using UPLC for >95% purity and 1H NMR 
for identification. 
2.16.d. Compound 29-46 were synthesized using a modification of a previously described 
technique.224 Derivatized trifluoroborates (0.25 mmol), derivatized bromobenzenes (0.25 
mmol), and cesium carbonate (0.756 mmol) was combined with catalytic [1,1′-
Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with dichloromethane 
(0.023 mmol) and the mixture was suspended in a degassed solution of THF and water 
(1:10, 5mL) in a 20mL microwave vial. The reaction was vortexed briefly and irradiated in 
a biotage initiator at 100 ○C for 1-2 hours until the starting material was consumed as 
determined by TLC as previously described. The reaction mixture was evaporated under 
reduced pressure, acidified using HCl and extracted 3x from DCM. The organic was dried 
over sodium sulfate and adsorbed onto isolute for separation using flash chromatography 




LiOH (0.5 mmol) and dissolved in methanol and water (3:1, 10mL). The reaction was 
microwave irradiated at 100 ○C for 1-2 hours until the ester starting material was 
consumed. The reaction was acidified, evaporated under reduced pressure, and vacuum 
filtered rinsing with cold HCl to yield a white solid 15. 
Carboxylic acid 15 (2 mmol) was lyophilized and resuspended in dry DCE (10 mL) under 
nitrogen in a flame dried flask. Oxalyl chloride (3.6 mmol) and catalytic DMF (5 drops) 
were added to the reaction on ice and the solution was allowed to stir at room temperature 
for 1-24 h until gas was no longer produced. The reaction generally turned yellow upon 
formation of the carbonyl chloride in solution. DCE was removed under reduced pressure 
using rotary evaporation to yield a bright yellow residue. The residue was resuspended in 
dry DCM (10mL) and in a separate flask, Aminobenzoate derivatives 17 were dissolved in 
dry DCM (10 mL) with TEA (8.2 equiv.). The basic aminobenzoate solution was added to 
the benzoyl chloride under nitrogen via cannula transfer and the reaction was stirred at 
room temperature under nitrogen for 1-24h until the amine starting material was consumed 
as confirmed by UPLC. The reaction mixture was filtered to remove the TEA salt, and the 
remaining liquid was extracted from ethyl acetate, rinsing sequentially with citric acid, 
NaOH and brine. The remaining organic layer was loaded onto a 25g silica column and 
purified using flash chromatography with a solvent gradient from 0-100% ethyl acetate in 
hexanes over 25 minutes. Fractions containing product 18 were combined and identity of 
products were confirmed using UPLC and NMR. 
The resulting ester 18 (1 mmol) was added to a microwave vial with LiOH (0.5 mmol) and 
dissolved in methanol and water (3:1, 10mL). The reaction was microwave irradiated at 




acidified, evaporated under reduced pressure, and vacuum filtered rinsing with cold HCl 
to yield product 29-46 as a white to off-white solid. 
Final products were lyophilized and analyzed using UPLC for >95% purity and 1H NMR 
for identification. 
2.16.d. Spectroscopy for Synthesized compounds: 
2: 
Intermediate: 1H NMR (CDCl3) δ: 3.795 (s, 2H), 5.797 (s, 1H), 6.697 (d, 1H, J = 8.8 Hz), 
7.422 - 7.450 (dd, 1H, J = 2.5, 8.8 Hz), 8.058 (d, 1H, J = 2.3 Hz). MS calcd for C5H6ClN3 
144.03 [M + H+], found 144.02 [M + H+]. 
Final product: 1H NMR (CDCl3) δ: 7.260-7.356 (m, 2H), 7.397-7.466 (m, 3H), 7.536-7.587 
(m, 4H), 7.506 (td, 1H, J = 1.6, 7.8 Hz), 8.136 (d, 1H, J = 2.2 Hz), 8.823 (dd, 1H, J = 4.9, 
0.7 Hz), 13.301 (s, 1H). MS calcd for C17H13ClN4 309.09 [M + H+], found 309.41 [M + H+] 
16: 
Intermediate: 1H NMR (400 MHz, CDCl3) δ3.90 (s, 3H), 7.25 (m, 1H), 7.42 (t, 1H), 7.51 
(t, 2H), 7.69 (m, 1H), 7.77 (t, 2H), 8.04 (m, 3H), 8.59 (d, 1H), 11.68 (s, 1H) 
Final Product: 1H NMR (400 MHz, CDCl3)δ7.19-7.23 (t, 3H), 7.59-7.64 (t, 3H), 8.09-
8.13 (m, 3H), 8.74, 8.76 (d, 1H), 8.87, 8.89 (d, 2H), 12.61 (s, 1H), 12.91 (s, 2H)  
23: 
Intermediate 1: 1H NMR (400 MHz, (CD3)2SO)δ 2.11 (s, 3H), 2.34 (t, 3H), 3.53 (s, 3H), 
7.16 (t, 1H), 7.26 (t, 1H), 7.35 (m, 3H), 7.50 (q, 1H), 7.59 (q, 2H), 7.68 (t, 2H), 7.91 (d, 




Final product: 1H NMR (400 MHz, (CD3)2SO)δ 2.07 (s, 3H), 7.12 (t, 1H), 7.26 (q, 1H), 
7.35 (q, 3H), 7.52 (q, 1H), 7.60 (t, 2H), 7.68 (d, 2H), 9.95 (s, 1H), 12.62 (s, 1H) 
24: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.92 (s, 3H), 7.44 (d, 1H), 7.53 (t, 2H), 7.62 
(d, 1H), 7.78 (m, 3H), 7.92 (d, 2H), 8.06 (d, 2H), 8.50 (q, 1H), 11.41 (s, 1H) 
UPLC Rt: 7.022 minutes 
Final product: 1H NMR (400 MHz, (CD3)2SO)δ 7.26(t, 1H), 7.40 (m, 3H), 7.60 (m, 3H), 
7.73 (d, 2H), 7.88 (d, 2H), 8.54 (q, 1H), 11.85 (s, 1H), 13.99 (s, 1H) 
25:  
Final product: 1H NMR (400 MHz, (CD3)2SO)δ 7.25 (m, 2H), 7.37 (m, 3H), 7.54 (d, 1H), 
7.61 (t, 2H), 7.69 (d, 2H), 7.91 (d, 2H), 10.04 (s, 1H), 13.01 (s, 1H) 
26: 
Final product: 1H NMR (600 MHz, CDCl3)δ 3.98 (d, 4H), 6.87 (q, 1H), 7.42 (t, 1H), 7.52 
(q, 3H), 7.66 (m, 4H), 7.78 (t, 2H), 8.14 (q, 4H), 8.82 (q, 1H) 
27: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.74 (s, 3H), 7.25 (m, 1H), 7.37 (m, 3H), 
7.52 (m, 1H), 7.61 (t, 2H), 7.70 (d, 2H), 7.95 (m, 2H), 8.34 (t, 1H), 10.37 (s, 1H) 
Final product: 1H NMR (600 MHz, (CD3)2SO)δ 7.39 (d, 1H), 7.53 (m, 3H), 7.69 (m, 1h), 








Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.67 (s, 3H), 7.24 (d, 1H), 7.34 (t, 2H), 7.59(d, 
3H), 7.69 (d, 2H), 7.81 (s, 4H), 7.92 (d, 2H), 10.45 (s, 1H) 
Final product: 1H NMR (600 MHz, (CD3)2SO)δ 7.42 (m, 2H), 7.54 (q, 2H), 7.68 (q, 1H), 
7.78 (d, 2H), 7.84 (d, 2H), 7.89 (d, 2H), 7.93 (d, 2H), 7.99 (d, 1H), 8.09 (d, 2H), 10.44 (s, 
1H) 
29: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.84 (s, 3H), 7.19 (m, 1H), 7.26 (d, 1H), 
7.34 (q, 2H), 7.45 (t, 2H), 7.54 (t, 2H), 7.63 (m, 2H), 7.82 (d, 1H), 8.17 (t, 1H), 8.85 (q, 
1H), 11.71 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 7.24 (q, 2H), 7.35 (q, 2H), 7.44 (t, 1H), 7.54 
(d, 2H), 7.66 (m, 2H), 7.83 (d, 1H), 8.06 (s, 1H), 8.82 (q, 1H), 11.71 (s, 1H) 
30: 
Final product: 1H NMR (400 MHz, CDCl3)δ 6.88 (q, 1H), 7.41 (d, 1H), 7.51 (t, 2H), 7.61 
(t, 1H), 7.71 (d, 2H), 7.84 (d, 1H), 8.01 (d, 1H), 8.20 (q, 1H), 8.31 (s, 1H), 8.80 (q, 1H), 
12.13 (s, 1H) 
31: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.62 (s, 3H), 6.89 (m, 1H), 7.10 (q, 2H), 
7.31 (q, 4H), 7.38 (m, 2H), 7.59 (t, 1H), 7.77 (q, 1H), 8.53 (d, 1H), 10.85 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 6.93 (t, 1H), 7.14 (m, 3H), 7.30 (m, 4H), 






Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.00 (s, 3H), 3.71 (s, 3H), 6.98 (t 1H), 7.21 
(m, 3H), 7.29 (q, 1H), 7.35 (m ,4H), 7.57 (q, 1H), 7.66 (q, 1H), 8.93 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 2.03 (s, 3H), 7.01 (d, 1H), 7.15 (d, 1H), 7.20 
(t, 2H), 7.27 (t, 2H), 7.32 (d, 2H), 7.38 (t, 1H), 7.67 (t, 2H), 8.70 (s, 1H) 
33: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.65 (s, 3H), 7.08 (m, 2H), 7.18 (t, 2H), 7.30 
(m, 4H), 7.37 (t, 1H), 7.44 (q, 1H), 7.58 (t, 1H), 8.54 (q, 1H), 10.66 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 7.14 (m, 4H), 7.28 (d, 1H), 7.34 (m, 2H), 
7.43 (m ,1H), 7.53 (q, 1H), 7.63 (m, 1H), 8.61 (q, 1H), 10.33 (s, 1H) 
34: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.68 (s, 3H), 7.02 (m, 1H), 7.12 (m, 1H), 
7.23 (t, 2H), 7.35 (m, 5H), 7.51 (d, 1H), 7.65 (t, 1H), 8.67 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 7.18 (m, 4H), 7.30 (q, 4H), 7.40 (t, 1H), 7.56 
(d, 1H), 7.69 (d, 1H), 8.48 (s, 1H) 
35: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.67 (s, 3H), 7.12 (m, 2H), 7.23 (m, 5H) 
7.31 (t, 1H), 7.37 (m, 2H), 7.50 (s, 1H), 7.55 (d, 1H), 7.66 (t, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 7.13 (q, 1H), 7.21 (q, 3H), 7.27 (t, 2H), 7.33 






Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.38 (s, 3H), 3.64 (s, 3H), 7.19 (s, 4H), 
7.36 (t, 2H), 7.49 (m, 1H), 7.79 (d, 1H) 
Intermediate 2: 1H NMR (400 MHz, CDCl3)δ 2.26 (s, 3H), 7.04(d, 2H), 7.13 (t, 2H), 
7.25(m, 2H), 7.42 (m, 1H), 7.81 (m, 1H), 10.55 (s, 1H) 
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ 2.01 (s, 3H), 2.19 (s, 3H), 3.69 (s, 3H), 
7.01 (m, 4H), 7.24 (m, 3H), 7.36 (q, 1H), 7.59 (d, 1H), 7.65 (d, 1H), 8.94 (s, 1H) 
Final product: 1H NMR (600 MHz, CDCl3)δ 2.355 (s, 3H), 7.19 (m, 4H), 7.37 (m, 3H), 
7.45 (m, 4H), 7.54 (m, 1H), 7.81 (m, 2H), 8.93 (s, 1H) 
37: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.63 (s, 3H), 3.81 (s, 3H), 6.91 (d, 2H), 
7.28 (d, 1H), 7.34 (t, 2H), 7.62 (t, 1H), 7.76 (m, 2H) 
Intermediate 2: 1H NMR (400 MHz, CDCl3)δ3.84 (s, 3H), 6.93 (t, 2H), 7.28 (q, 2H), 7.38 
(q, 2H), 7.54 (m, 1H), 7.92 (t, 1H) 
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ 3.61 (s, 3H), 3.66 (s, 3H), 6.67 (d, 2H), 
6.93 (t, 1H), 7.33 (m, 6H), 7.59 (d, 1H), 7.77 (d, 1H), 8.63 (d, 1H), 10.77 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 3.58 (s, 3H), 6.68 (d, 2H), 6.96 (m, 1H), 
7.11 (s, 1H), 7.20 (d, 2H), 7.29 (m, 2H), 7.37 (m, 1H), 7.46 (t, 1H), 7.59 (t, 1H), 7.86 (q, 








Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.24 (s, 3H), 3.74 (s, 3H), 7.09 (q, 1H), 
7.24 (m, 1H), 7.34 (m, 3H), 7.44 (t, 1H), 7.52 (q, 2H), 7.64 (m, 1H), 7.71 (q, 1H), 7.84 (m, 
1H), 8.12 (t, 1H), 10.01 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 2.27 (s, 3H), 7.14 (t, 1H), 7.23 (t, 1H), 7.34 
(t, 3H), 7.46 (t, 1H), 7.54 (t, 1H), 7.61 (d, 2H), 7.72 (d, 1H), 7.78 (d, 1H), 8.15 (s, 1H), 
9.90 (s, 1H), 12.69 (s, 1H) 
39:  
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.72 (s, 3H), 3.75 (s, 3H), 7.09 (m, 1H), 
7.43 (m, 3H), 7.52 (t, 2H), 7.63 (q, 4H), 7.77 (d, 1H), 7.86 (q, 3H), 8.13 (t, 1H), 9.87 (s, 
1H) 
Final product: 1H NMR (600 MHz, CDCl3)δ  7.41 (m, 3H), 7.58 (m, 3H), 7.81 (d, 1H), 
7.88 (m, 2H), 7.94 (d, 1H), 8.00 (d, 1H), 8.11 (m, 2H), 8.37 (t, 2H), 9.88 (s, 1H) 
40: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.00 (s, 3H), 3.71 (s, 3H), 6.98 (t, 1H), 7.21 
(m, 3H), 7.27 (q, 1H), 7.34 (m, 4H), 7.57 (q, 1H), 7.66 (q, 1H), 8.93 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ 2.02 (s, 3H), 7.02 (t, 1H), 7.18 (m, 3H), 7.27 
(t, 3H), 7.32 (d, 2H), 7.38 (q, 1H), 7.66 (t, 2H), 8.71 (s, 1H) 
41: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.62 (s, 3H), 6.59 (m, 1H), 7.38 (m, 7H), 




Final product: 1H NMR (400 MHz, CDCl3)δ 6.72 (m, 1H), 7.19 (m, 5H), 7.36 (m ,2H), 
7.44 (m, 2H), 7.54 (m, 1H), 7.71 (q, 1H), 7.95 (q, 1H), 8.60 (q, 1H), 10.73 (s, 1H) 
42: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.38 (s, 3H), 3.92 (d, 3H), 7.24 (d, 2H), 
7.51 (q, 2H), 7.68 (d, 2H), 8.10 (t, 2H) 
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ2.36 (s, 3H), 3.96 (s, 3H), 7.24 (m, 3H), 
7.49 (d, 3H), 7.70 (m, 3H), 8.01 (d, 2H), 8.88 (q, 1H), 11.89 (s, 1H) 
Final product: 1H NMR (600 MHz, (CD3)2SO)δ 2.36 (s, 4H), 7.28 (d, 2H), 7.56 (m, 1H), 
7.67 (d, 2H), 7.77 (q, 1H), 7.88 (d, 2H), 8.04 (d, 2H), 8.72 (q, 1H), 11.83 (s, 1H) 
43:  
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 2.38 (s, 3H), 3.64 (s, 3H), 7.19 (s, 4H), 
7.36 (t, 2H), 7.49 (m, 1H), 7.79 (d, 1H) 
Intermediate 2: 1H NMR (400 MHz, CDCl3)δ 2.26 (s, 3H), 7.04(d, 2H), 7.13 (t, 2H), 
7.25(m, 2H), 7.42 (m, 1H), 7.81 (m, 1H), 10.55 (s, 1H) 
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ2.65 (s, 3H), 3.62 (s, 3H), 6.92 (d, 2H), 7.02 
(m, 3H), 7.14 (m, 4H), 7.24 (m, 3H), 7.33 (m, 1H), 7.41 (q, 1H), 7.51 (d, 1H), 7.79 (s, 
1H), 8.51 (q, 1H), 10.66 (s, 1H) 
Final product: 1H NMR (400 MHz, MeOD)δ 2.30 (s, 3H), 7.15 (d, 2H), 7.32 (m, 3H), 
7.50 (t, 2H), 7.60 (t, 1H), 7.68 (q, 1H), 8.63 (q, 1H) 
44: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ3.62 (s, 3H), 3.68 (s, 3H), 6.95 (m, 3H), 




Intermediate 2: 1H NMR (400 MHz, CDCl3)δ 3.55 (s, 3H), 6.72 (d, 1H), 6.89 (q, 1H), 
6.98 (d, 2H), 7.11 (t, 1H), 7.18 (m, 2H), 7.29 (m ,3H), 7.41 (q, 1H), 7.78 (q, 1H) 
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ 2.97 (s, 3H), 3.59 (s, 3H), 3.82 (s, 3H), 
6.76 (d, 1H), 6.90 (q, 1H), 7.00 (m, 2H), 7.30 (m, 2H), 7.46 (q, 1H), 7.53 (m, 2H), 7.62 (q, 
2H), 8.05 (s, 1H), 8.77 (q, 1H), 10.86 (s, 1H)  
Final product: 1H NMR (400 MHz, CDCl3) 1.69 (s, 3H), 3.69 (s, 3H), 7.00 (t, 2H), 7.17 
(m, 3H), 7.31 (m, 3H), 7.60 (m, 2H), 9.52 (s, 1H)  
45: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ2.41 (s, 3H), 3.94 (s, 3H), 7.27 (t, 1H), 7.48 
(d, 1H), 7.52 (d, 2H), 8.00 (q, 1H), 8.27 (d, 1H) 
Intermediate 2: 1H NMR (400 MHz, CDCl3)δ 2.19 (s, 3H), 7.13 (d, 2H), 7.42 (t, 3H), 7.73 
(t, 2H), 7.99 (s, 1H) 
13C NMR (400 MHz, D2O)δ167.7, 140.87, 136.80, 131.87, 131.34, 130.18, 129.79, 
128.43, 127.47, 127.06, 21.13 
Intermediate 3: 1H NMR (400 MHz, CDCl3)δ2.42 (s, 3H), 3.96 (s, 3H), 7.28 (d, 2H), 7.34 
(m, 1H), 7.57 (t, 3H), 7.75 (m, 2H), 7.97 (t, 1H), 8.92 (q, 1H), 11.96 (s, 1H) 
Final product: 1H NMR (400 MHz, CDCl3)δ2.34 (s, 3H), 7.26 (s, 2H), 7.42(s, 1H), 7.57 
(s, 3H), 7.81, 7.90 (d, 3H), 8.21 (s, 1H), 8.95 (s, 1H), 12.16 (s, 1H) 
46: 
Intermediate 1: 1H NMR (400 MHz, CDCl3)δ 3.79 (s, 3H), 6.99 (m ,1H), 7.25 (m, 2H), 
7.54 (m, 2H), 7.65 (m, 1H), 7.76 (m, 1H), 7.86 (m, 1H), 7.94 (q, 1H), 8.00 (m, 1H), 8.14 




Final product: 1H NMR (400 MHz, CDCl3)δ 7.11 (m ,1H), 7.34 (m ,1H), 7.43 (q, 2H), 
7.54 (t, 1H), 7.65 (m, 3H), 7.76 (m, 1H), 7.98 (m, 1H), 8.12 (q, 1H), 8.22 (t, 1H), 8.90 (q, 
1H), 11.96 (s, 1H) 
 
2.17. Antibodies 
KDM4B: AbCam, Cat# ab191434 
KDM4E: Novus, Cat# NBP2-49124 
H3K9me3: Abcam, Cat# ab176916 
H3K4me: Active Motif, Cat# 39297 
H3K4me2: Abcam, Cat# ab32356 
GAPDH: Abgent, Cat# AP7873b 
Goat anti-rabbit: Vectorlabs, Cat# BA-1000 
Fluorescent secondaries:  
Goat anti-rabbit: AbCam, Cat# ab150078 
2.18. Primers 
TaqMan® Gene Expression Assay Primers (ThermoFisher) 
 GAPDH: Mm99999915_g1 
 IL-6: Mm00446190_m1 
 TNF-α: Mm00443258_m1 
 IL-10:  Mm01288386_m1 




 IL-1b: Mm00434228_m1 
 Era: Mm00469669_m1 
 
Chapter Three: Inhibition of the Histone Demethylase KDM4B Leads to Activation 
of KDM1A, Attenuates Bacterial-Induced Pro-Inflammatory Cytokine Release and 
Reduces Osteoclastogenesis. 
3.1. Rationale and Hypothesis 
Periodontal disease (PD) causes irreversible tissue damage and bone loss and 
affects 46% of adult Americans. PD is a common chronic inflammatory disease 
characterized by destruction of the supporting structures of the teeth.50, 186 This chapter 
describes a novel approach that targets epigenetic control of gene expression in the host 
to resolve the pro-inflammatory immune response driving PD.  
The pro-inflammatory cytokines TNF-α and IL-6 are classically upregulated in 
gingival connective tissues of PD patients, 36 and these cytokines are secreted from perio-
pathogen activated macrophages through toll like receptor (TLR) signaling.225 TLR4 
binding by periopathogenic LPS activates a signaling cascade that drives both cytokine 
and chemokine production. KDM4B and its major substrate, H3K9, have been linked to 
this process by several research groups. 157-159, 192 Because of this, we hypothesize that  
KDM4B is a mediator of PD progression, and demonstrate that its demethylation activity 
is a signature of several pro-inflammatory processes. 
 It is well known that histone demethylase enzymes are conserved throughout 




among different classes and families, and are coordinated in their activity. Multiple studies 
support the idea that H3K4 and H3K9 methylation are mutually exclusive states.184, 226 For 
example, cross talk between KDM4B and KDM1A enzymes leads to a balanced system 
wherein lysine 9 methylation serves as a prerequisite to lysine 4 demethylation by 
KDM1A.184 Because it is known that the demethylation activity of KDM1A on Histone 3 
lysine 4 leads to repression of pro-inflammatory cytokine gene transcription,183  we 
postulate that KDM4B is a positive regulator of the pro-inflammatory cytokine response 
through an indirect mechanism by inhibiting KDM1A.  
The current study aims to interrogate the activity of KDM4B as it relates to the 
immune response in periodontal disease through the use of the JMJD2 demethylase 
inhibitor ML324.212 We hypothesize that KDM4B inhibition using this inhibitor will result in 
a reduced immune response to bacterial LPS, and that ML324 could prove useful as a 
chemical tool and lead compound for future studies on PD or other hyper-inflammatory or 
autoimmune diseases. 
3.2. Results 
3.2.a. KDM4B and KDM4E protein abundance is increased in areas of periodontal 
inflammatory infiltrate. 
To test the hypothesis that KDM4B is overexpressed upon LPS stimulation, 
histological sections from the calvariae of mice that had been injected daily for 5 days with 
fixed Aggregatibacter actinomycetemcomitans (A.a) or PBS were stained for KDM4B 
protein. An increase in resorption pits due to osteoclast activity was observed in calvariae 
treated with A.a, confirming this as a viable model for periodontal disease.217 Staining for 




sections most active with inflammatory 
infiltration. This region of interest showed a   
significantly higher concentration of KDM4B 
protein (Figure 3.1A), indicating that 
KDM4B protein levels correlate with immune 
activation in periodontal disease. The 
experimental inhibitor ML324 has also been 
shown to inhibit the related demethylase 
KDM4E,212 but this protein is not found in 
mice. Therefore, tissue sections from 
periodontally diseased human patients and 
healthy controls were stained for both 
KDM4E and KDM4B using 
immunohistochemistry. The connective 
tissue underlying the oral epithelium was 
chosen as the region of interest for analysis. 
A statistically significant increase in both 
KDM4B and KDM4E abundance was 
observed in diseased versus healthy tissues 
(Figure 3.1B), demonstrating that KDM4 
enzymes are implicated in periodontal 
disease status. 
  
Figure 3.1. KDM4B abundance is significantly increased 
in periodontal diseased versus healthy tissues. Live A.a 
was injected subcutaneously into 12-week old C57BL/6 mice 
at the mid-sagittal region of the calvarium every day for 5d. 
Paraffin embedded sections were stained for F4/80, TRAP 
and KDM4B using immunohistochemistry, all of which were 
significantly upregulated in diseased versus healthy 
calvariae. 10x Images presented are representative of the 
data set. (A)  In clinical periodontal specimens, the region of 
interest was defined as the connective tissue underlying the 
oral epithelium. Paraffin embedded sections were stained for 
KDM4E and KDM4B using immunohistochemistry, both of 
which were upregulated in diseased versus healthy patient 
tissues. 20x images are representative of the data set. (B) 
positive pixels quantified using color thresholding in ImageJ. 
Data are presented as mean ± SD. Significance was 
determined using a one-tailed Wilcoxon ranked sum test. 
Epithelium (E) Calvarial Bone (C) Brain (B) *p<0.05, 






3.2.b. ML324, previously defined as a KDM4E inhibitor, shows inhibitory 
activity against KDM4B. 
ML324 was docked into the active site of the KDM4A-E family in flexible mode, and was 
found to have high computational selectivity for the KDM4B active site (Figure 3.2A). 
ML324 exhibited a lower average binding energy to the KDM4B active site (-53.04 
kcal/mol) for the top 30 conformers versus KDM4E (-42.52 kcal/mol). Additionally, we used 
an Alphascreen® assay to determine the effect of ML324 on the demethylation activity of 
KDM4B. Here we show that ML324 has inhibitory activity towards KDM4B, with an IC50 
value of 4.9 μM (Figure 3.2B). Additionally, we have defined the EC50 of ML324 for 
translational immunosuppression in primary macrophages to be 31 μM (Figure 3.2C). IL-
6 production drives periodontal disease pathogenesis, therefore the ability of ML324 to 
effectively reduce the production of this cytokine emphasizes the potential of KDM4B 
inhibitors as therapeutics for PD treatment. 
3.2.c. KDM4B inhibition using ML324 results in a significantly reduced cytokine  
immune response to Aa-LPS in macrophages. 
After a 1-hour pre-tr  eatment with ML324 (50 μM) followed by an inflammatory Aa-LPS  
challenge (100 ng/mL), ELISA and PCR analysis revealed that the KDM4B inhibitor 
ML324 significantly reduced the levels of inflammatory cytokines in primary murine 
macrophages (Figure 3.3A-D). At 8- and 24-hour time points and in both male and female 
cells, ML324 was able to significantly reduce IL-6 and TNF-α transcription and translation 
compared to LPS treatment with vehicle control (DMSO). A pan-selective KDM4 family 
inhibitor, JIB-04, was also able to produce this effect in most groups, but with a more 




change or a significant increase compared to 
vehicle controls in the majority of groups.  These 
data demonstrate not only that KDM4B 
inhibition reduces inflammatory cytokine 
production but also that this effect is specific to 
KDM4B over the KDM4 family as a whole. It is 
important to note, however, that  enzyme 
kinetics and mode of binding of ML324 to 
KDM4B have not been described, although the 
in vivo pharmacokinetics and ADME properties 
of this compound are extremely favorable.212  
Additionally, this data shows that as 
hypothesized, the activity of KDM4B and 
KDM1A are negatively correlated; and that 
inhibiting KDM1A via GSK-LSD1 gives an 
opposing effect on inflammatory cytokine 






Figure 3.2. ML324 demonstrates inhibitory 
activity towards KDM4B and causes dose 
dependent immunosuppression. The KDM4A-E 
protein crystal structures were subjected to 
unbiased docking of ML324 where the top 30 
conformers in the active site were used for 
analysis (A). KDM4A and C had no poses of 
ML324 dock into the active site of these enzymes, 
therefore this data is not displayed. Inhibition of 
KDM4B was assessed using an 11-point IC50 
determination using the histone demethylase 
AlphaScreen (PerkinElmer) assay in triplicate 
resulting in an IC50 of 4.9 μM (B). The EC50 for 
immunosuppression using ML324 was determined 
to be 31 μM by measuring supernatant IL-6 protein 
following a 24h Aa-LPS stimulation with variable 
concentrations of ML324 in primary BMDM cells 
(C). Cells were treated for 1h with each indicated 
concentration of ML324, followed by Aa-LPS 
challenge for 24h. The data were normalized as a 
percentage of the maximal IL-6 response in 
response to LPS. Data for all panels are 





3.2.d. KDM4B inhibition using ML324 results in a significant reduction in 
osteoclastogenesis. 
After 5 days of priming bone marrow-derived hematopoietic stem cells into pre-osteoclasts 
using macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear 
factor kappa β ligand (RANK-L), osteoclastogenesis was significantly increased in cells 
treated with RANK-L or Aa-LPS for 3 days compared to PBS treated cells, and this effect 
was lost in cells pre-treated with ML324 (10 μM). TRAP+, multinucleated cells were 
significantly increased in both cells treated with Aa-LPS as well as RANK-L compared to 
PBS treated control cells. By contrast, in cells that were pre-treated with ML324, there was 
no significant difference in osteoclast formation compared to control groups, regardless of 
 
Figure 3.3. KDM4B inhibition significantly reduces the A.a LPS-induced immune response in primary 
macrophages. Male (A) and female (B) murine bone marrow derived macrophages were pre-treated for 1h with the 
selective KDM4B inhibitor, ML324, a family-wide KDM4 inhibitor, JIB-04, and a KDM1A inhibitor, GSK-LSD1 or DMSO 
vehicle. Following drug treatment, cells were challenged with Aa-LPS for 8 and 24h, where gene expression and 
supernatant protein concentration were measured via rt-qPCR relative to GAPDH and ELISA relative to a standard 
curve. Data was normalized as a percentage of the maximal response (red) in each group for display. (C,D). N=4 per 
experiment, data is representative of 3 experiments. Data are presented as mean ± SD. Statistical significance was 
determined using a repeated measures ANOVA with multiple comparisons. ***p<0.001, **p<0.01, *p<0.05 compared to 







whether cells were stimulated with Aa-LPS or RANK-L. Additionally, formed osteoclasts 
appeared smaller, and had less intense TRAP staining (Figure 3.4).  
3.2.e. Immunosuppressive effects of KDM4B inhibition act indirectly, through 
demethylation of H3K4 by KDM1A.  
To understand the mechanism for KDM4B inhibition induced immunosuppression, we 
used the RAW264.7 macrophage cell line, which is the best representation of primary  
bone marrow derived macrophages.227 Interestingly, when cycloheximide (5 μg/mL) was 
co-administered with ML324 (50 μM) prior to Aa-LPS challenge in these cells, the ability 
 
Figure 3.4. KDM4B inhibition via ML324 prevents osteoclast formation induced by either A.a LPS or RANK-L. 
Murine bone marrow was differentiated into osteoclasts by supplementation of the hematopoietic compartment with 
M-CSF for 3 days and RANK-L + M-CSF for 2 days, where cells were rinsed and pre-treated for 1h with M-CSF and 
ML324 or DMSO vehicle followed by supplementation with RANK-L or A.a LPS. After 72 hours, cells were fixed and 
stained for tartrate resistant acid phosphatase. 3 representative images were taken of each well, and TRAP+, 
multinucleated cells were counted in each field. 10x representative images of M1 and F2 are displayed. (A) Each 
mouse (M1, M2 = male; F1, F2 = female) independently showed a significant increase in osteoclast formation in 
response to LPS or RANK-L alone compared to PBS controls, but no significant difference in osteoclast formation 
was observed between PBS and ML324 + LPS or ML324 + RANK-L treated cells (B). Male cells exhibit increased 
osteoclastogenesis in response to RANK-L or A.a LPS compared to female cells. (C) Data is presented as the mean 
number of osteoclasts in each field ± SD. Statistical significance was determined using a paired Friedman test or 
two-way ANOVA with multiple comparisons at an α = 0.05. *p<0.05, **p<0.01 n = 3 fields per well, 2 wells per group, 








of ML324 to reduce LPS-induced cytokine production is lost (Figure 3.5A). Because 
cycloheximide 
inhibits eukaryotic 




relies on new protein 
synthesis, and that 
the reduced cytokine  
response to LPS is 
not a direct effect of 




To determine if the 
cellular response to 
LPS altered KDM4B 
expression levels, we 




Figure 3.5. KDM4B inhibition mediated immunosuppressive effect is indirect, 
requiring new protein synthesis and increased KDM1A activity. New protein 
synthesis is required for the immunosuppressive effects of ML324 on the LPS-induced 
immune response (A). Cells were pre-treated with cycloheximide (5ug/mL) for 4 h with 
or without ML324 (50 μM) followed by Aa-LPS challenge (100ng/mL) for 16h where 
RNA was collected and analyzed using qRT-PCR to measure IL-6 expression 
compared to GAPDH as an endogenous control. Statistical significance was 
determined using a repeated measures ANOVA with multiple comparisons. 
Demethylation at H3K4 is significantly decreased in cells following LPS treatment, but 
the effect is reversed upon addition of ML324. (B) ML324 treatment causes a 
significant increase in H3K9me3 but not KDM4B, and these marks are not affected by 
LPS treatment alone. (C) RAW264.7 cells were pre-treated for 1h with ML324 followed 
by Aa-LPS challenge for 24h where H3K4 mono-methylation was measured in fixed 
cells using immunofluorescent antibody to H3K4me at 10x. KDM1A activity is 
significantly decreased following Aa-LPS treatment alone, but in combination with 
ML324 pretreatment, KDM1A activity is increased. n = 3 wells, 48 fields/well, **p<0.01. 
Data are represented as mean ± SD. Statistical significance was determined using 






Omnibus (GEO) profiles). There was no change in mRNA expression of KDM4B in 
response to LPS, suggesting that the activity of KDM4B as opposed to its expression level 
drives the immune response to LPS. Further, KDM4A, KDM4C, and KDM4D also show 
no significant differences in expression in response to LPS. To confirm that the activity of 
 
Figure 3.7. KDM4B inhibition reduces A.a.-induced inflammation in vitro and modifies calvarial bone loss 
pattern in vivo. ML324 reduced fixed A.a induced inflammatory cytokine production in bone marrow derived 
macrophages. (A) 12-week old C57BL/6 were injected subcutaneously and supraperiosteally at the mid-sagittal suture 
daily for 5d with either A.a alone, A.a + drug or DMSO as a negative control. Mice were sacrificed on day 6, where 
calvarial tissue was homogenized and protein isolated for western blot analysis of H3K9me3 compared to GAPDH as 
internal control. (B) Calvarial bones were dissected and micro-computed tomography was run using a Scanco40 
instrument at a 15μm resolution.(C) A region of interest was defined as a 150 mm3 cylinder centered at the bregma 
point (intersection of the frontal and parietal bones at the midline). Total bone volume at this area was quantified using 




KDM4B was altered in response to LPS, the histone methylation marks H3K4me and 
H3K9me3 were monitored by immunofluorescence following ML324 pre-treatment (50 
μM) and Aa-LPS challenge. Concurrent with the absence of change in mRNA levels of 
KDM4B, there was no significant difference in KDM4B protein levels between groups 
(Figure 3.6). In contrast, the activity of KDM4B was decreased following ML324 pre-
treatment as evidenced by a significant increase in H3K9me3. Interestingly, there was not 
a significant difference between control and LPS treated cells (Figure 3.5B). Conversely, 
H3K4me levels significantly decreased following A.a.LPS challenge, but ML324 pre-
treatment not only reversed this effect, but caused a significant increase in H3K4me levels 
compared to PBS controls (Figure 3.5B). These data together suggest that H3K4 
methylation is differentially regulated by inflammatory stimuli in macrophages, and this 
activity can be modulated indirectly through pharmacological inhibition of KDM4B. 
3.2.f. KDM4B inhibition using ML324 and Experimental Inhibitor 36 Results in 
Altered A.a-Induced Bone Loss 
Phenotype  
To recapitulate the anti-inflammatory 
effects of ML324 treatment in vitro, 
we used a 5-day  murine calvarial 
model of periodontal disease using 
Aggregatibacter 
actinomycetemcomitans induced 
bone loss to probe the in vivo efficacy 
of KDM4B inhibition. First, we verified 
 
Figure 3.6. KDM4 family gene expression is unaltered in 
response to LPS treatment. KDM4A-D mRNA expression in 
primary bone marrow derived macrophages following 
lipopolysaccharide stimulation for 24h. Data were obtained from 
NCBI Gene Expression Omnibus profiles 






that ML324 was able to reduce fixed A.a induced cytokine production, as all previous 
experimentation was done using isolated LPS from A.a. We found that ML324 significantly 
reduced A.a-induced inflammatory cytokine production to the same degree that it was  
 
Figure 3.8. ML324 alters macrophage polarization. KDM4B inhibition alters macrophage metabolism in response 
to A.a LPS. Primary BMDMs were isolated and differentiated as previously described and were pre-treated with 
ML324 at 50uM for 1 hour followed by A.a LPS (100ng/mL). 24 hours later, extracellular flux was analyzed using a 
seahorse XFe96 instrument and following metabolic analysis, cells were incubated with phalloidin 488 and DAPI. 





previously shown to inhibit A.a LPS-induced inflammatory cytokine production. (Figure 
3.7A) Mice were injected subcutaneously supraperiosteal to the calvarial bone with both 
fixed whole A.a or PBS control and ML324, 36 or DMSO control for 5 days, and calvariae 
and tissues overlying the calvarial bone were collected following sacrifice. We found that 
in ML324 treated animals, H3K9me3 protein abundance was higher on average although 
insignificant, suggesting the effect was on target and that KDM4B was indeed inhibited in 
vivo. (Figure 3.7A) Unfortunately, we didn’t observe this effect with the experimental 
inhibitor we tested, 36. This could be due to absorbance or metabolism issues, as neither 
of these things were tested in our experimentation. Using micro-computed tomography, 
we analyzed total bone volume for a specific region of interest that spans 10mm x 10mm 
centered over the mid sagittal suture between the anterior and posterior calvarial bone. 
(Figure 3.7C) Unfortunately, there was a highly variable and not robust enough response 
to A.a treatment to discern any significant differences in our treatment groups. (Figure 
3.7D) We did, however, observe a very consistently high average bone volume within our 
region of interest for both ML324 and 36 treated animals. (Figure 3.7B) Overall, these 
data suggest that KDM4B inhibition may serve as a useful therapeutic intervention for 
prevention of periopathogen-induced bone resorption in vivo, but further experimentation 
is needed. 
3.2.g. ML324 alters A.a LPS-induced macrophage polarization 
As previously mentioned, literature suggests that KDM4B may be involved in macrophage 
polarization,46, 228-229 therefore we wanted to test whether ML324-induced 
immunosuppression was due to M2 polarization or de-differentiation of macrophages. 




treated with ML324 at 50 μM for 1 hour followed by A.a LPS (100ng/mL). 24 hours later, 
mRNA was isolated and IL-10 expression was quantified using qRT-PCR and ML324 pre-
treated cells were found to have significantly higher IL-10 expression. (Figure 3.8A) To 
determine if macrophages were M2 polarized, Extracellular flux was analyzed using a 
seahorse XFe96 instrument as previously described.230 We found that LPS treated cells 
are more glycolytic than PBS control cells, and ML324 pre-treatment rescued this effect. 
(Figure 3.8B) Additionally, cells treated with LPS, with or without ML324 exhibit a reduced 
spare respiratory capacity compared to PBS control treated cells. (Figure 3.8C) These 
data suggest that ML324 pre-treatment alters macrophage metabolism with an overall 
reduction in metabolic activity. To further probe macrophage polarization, we fluorescently 
stained both the cytoplasm and nuclei of cells to visualize cell morphology, as clear 
morphological differences are known to exist between M0 (un- or de- differentiated 
macrophages), M1 (pro-inflammatory) or M2 (anti-inflammatory) macrophages.231 We 
found that LPS treated macrophages exhibited an M1 phenotype, and ML324 pre-
treatment was able to rescue this effect, appearing very similar to PBS control treated 
cells. (Figure 3.8D) 
Chapter 4: Discovery of anti-periodontitis biphenyl-carboxamido-benzoic acids via 
Phenotypic Screening Guided QSAR. 
4.1. Rationale and Hypothesis 
Previous data from the project laboratory implicates KDM4B as a regulatory 
enzyme in periodontal disease progression through its role in suppressing both 
osteoclastogenesis and inflammatory cytokine production in primary macrophages.232 The 




literature to be the source of the 
tissue damage and bone loss 
characteristic of the disease.50 Still, 
therapeutic development has been 
aimed towards local antimicrobials 
such as chlorhexidine (PerioChip), 
doxycycline (Periostat) and 
minocycline (Arestin). Nevertheless, 
these therapies provide a moderate 
clinical benefit at best,7 and require strict patient compliance with visits required as often 
as every three months, which is rarely covered by insurance premiums. While the 
microbial component of periodontal disease is indeed critical to disease pathogenesis,50, 
64, 233 these therapies are applied by clinicians following standard of care treatment – which 
is to remove plaque biofilms through scaling and root planning (SRP), effectively leaving 
little to no microbial load immediately following treatment.233 Disease recurrence is driven 
rather by a continuation of immune activation and an inability for the periodontal wounds 
to heal.234-235 Given this information, one can imagine that a local immunosuppressive drug 
would afford some benefit, allowing the host immune system to resolve, wounds to heal, 
and ultimately preventing disease recurrence. The failure of previously explored anti-
inflammatory agents is likely due to their surface level targets such as secreted effector 
proteins that do not cause heritable changes beyond single cell divisions. Epigenetic 
therapeutics offer an advantage in this regard as they seek to reverse detrimental 
environmental changes that have the ability to propagate harmful disease processes. 
 
Figure 4.1. Compounds used to physicochemically cluster 
screening data. Compounds 4,6 and 7 are previously published 





In 2012, the NIH molecular libraries program reported the discovery of N-(3-
(dimethyamino)propyl-4-(8-hydroxyquinolin-6-yl)benzamide(1), a small molecule inhibitor 
specifically targeting KDM4E.212 While this compound was shown to inhibit viral replication 
of herpes simplex virus and cytomegalovirus, and later shown to induce depression in 
mice at high doses,236 the compound was not probed for additional activity. We recently 
reported that ML324, 8, is active toward a closely related enzyme, KDM4B, and has 
immunosuppressive action in murine macrophages.232 While this compound exhibits good 
cell permeability, it is highly insoluble at effective doses and requires a 14-step synthesis 
 
Figure 4.2. Consensus orthogonal in silico docking strategy yielded novel and commercially available 
immunosuppressive compounds. The public ZINC compound database was filtered and refined prior to docking to 
increase computational efficiency as well as after docking to eliminate PAINS and false positives/negatives (A). 
Compounds that ranked in the top 70% of both docks were physicochemically clustered and the cluster containing 
ML324 and JIB-04 was sorted based on binding affinity(B). The top 8 compounds (C) were purchased from Vitas 
laboratories. Compounds overlay space taken by natural ligands (D) 2-oxoglutarate (green), H3K9me3 (teal), KDM4B 








for development of new derivatives.212 Because of this, we sought to determine novel 
scaffolds with the potential to inhibit KDM4B, cause immunosuppressive effects, and 
potentially serve as optimizable compounds for localized treatment of periodontal disease.  
The current study utilized a multidisciplinary approach that combined consensus 
computational docking data with phenotypic screens using primary murine macrophages  
 
Figure 4.3. Phenotypic screening data for compounds identified by in silico docking suggests compound 16 is 
a promising hit for further development. Several initial hits caused suppressed the immune response to A.a LPS in 
vitro. (A) n=2 Compound 16 was further evaluated for dose-dependent immunosuppression, N = 4 (B) as well as for 
KDM4B inhibitory activity through measurement of H3K9me3 using fluorescent immunostaining, N = 3. (C,D) *p<0.05, 
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to identify a derivatizable scaffold with KDM4B inhibitory action. We further used this 
strategy to optimize our lead compounds and ultimately identified compound 46 as a 
Table 4.1. Novel compounds synthesized. 
 
Compound Scaffold R1 R2 R3 R4 R5 R6 R7 
16 1 H COOH H H H H H 
23 1 H COOH H H H CH3 H 
24 1 H COOH H F H H H 
25 1 H COOH H H H F H 
26 1 H COOH H H F H H 
27 1 H H COOH H H H H 
28 1 H H H COOH H H H 
29 2 H COOH H F H H H 
30 2 H COOH H H F H H 
31 3 H H COOH H H H H 
32 3 H H COOH H H H CH3 
33 3 H H COOH H F H H 
34 3 H H COOH H H H H 
35 3 H H H COOH H H H 
36 3 CH3 H COOH H H H CH3 
37 3 O-Me H COOH H H H H 
38 2 H COOH H H F CH3 H 
39 2 H COOH H H H F H 
40 3 H H COOH H H H CH3 
41 3 H H COOH H H H H 
42 1 CH3 COOH H F H H H 
43 3 CH3 H COOH H F H H 
44 3 H O-Me COOH H H H CH3 
45 2 CH3 COOH H H H CH3 H 


































potent immunosuppressive compound that could be used to treat periodontal disease  
4.2. Results 
4.2.a. Consensus computational docking followed by physicochemical clustering 
yields commercially available immunosuppressive compounds 
The ZINC database of molecules237 was filtered to retrieve compounds that were proposed 
to have in vitro activity as well as compounds that could be purchased. This library was 
further filtered to remove any potential pan-assay interference compounds (PAINS)238 as 
 




well as compounds with Lipinski violations, cytotoxic or unfavorable features239 (Figure  
4.2A).  The remaining compounds were subjected to high throughput screening for activity 
towards the KDM4B active site using two separate software programs (DOCK6.5, 
Molecular Operating Environment). The consensus activity data240 was consolidated into  
8,000 top compounds that were clustered based on similarity of their physicochemical 
properties241 (Figure 4.2B) and the top compounds that were physicochemically similar to 
 
Figure 4.4. Derivatives of 16 cause immunosuppression and were used to develop a binary QSAR model. The 
phenotypic immunosuppressive screen data (A) was converted into binary data using statistical significance (P<0.05) as 
a cutoff. A contingency analysis was run on the tested compounds to identify the physicochemical descriptors that were 
most highly correlated with activity. The top 12 descriptors from this analysis were used (Table 4.2) to map a quantitative 
structure activity relationship using Molecular Operating Environment software that had accuracy to predict actives of 
100% and inactives of 100% (B). 30 compounds were predicted to have activity with >70% confidence, and this subset 
included our current lead compound 42 (red). (C) *p<0.05, **p<0.01, ****p<0.0001 compared to DMSO control via one-























































































































previously identified KDM4B inhibitors212, 242-243 were purchased for in vitro evaluation 
(Figure 4.2C,D).  
4.2.b. 2-([1,1'-biphenyl]-4-carboxamido)benzoic acid causes dose-dependent 
immunosuppression and increased H3K9me3 
Several compounds from this initial clustered data set were active and suppressed 
the immune response to A.a LPS at 50 μM (Figure 4.3A). We decided to move forward 
with 11 because of its three membered structure and multiple routes of straight forward 
combinatorial chemistry-based synthesis. Before investing significant time in development 
of derivatives of 12, we confirmed a dose-dependent immunosuppressive response to A.a 
LPS (Figure 4.3B) with a concurrent increase in H3K9me3 (4.3C, D), suggesting the effect 
was on target.  
4.2.c. Development of efficient synthetic methods for 2-([1,1'-biphenyl]-4-
carboxamido)benzoic acid derivatives 
Sixteen derivates (Table 4.1; 13-28) were synthesized using a 5-step microwave 
assisted synthesis from derivatized bromobenzenes, phenyltrifluorborates and 2-amino 
benzoates (Scheme 4.1). Potential compounds were developed in silico, using 
commercially available and economical starting materials. This library was docked to the 
active site of KDM4B using consensus screening and hits were ranked based on binding 
affinity. Top derivatives predicted by consensus scores as well as easy to synthesize 
derivatives were synthesized. The first step of synthesis was a microwave assisted Suzuki 




step was microwave-assisted saponification to cleave the ester into a reactive carboxylic 
acid. The third step was further 
activated the carbonyl into a 
carbonyl chloride followed by 
addition of an aminobenzoate 
under basic conditions to yield the 
final three-membered ester. The 
resulting ester was cleaved in the 
final step using the same 
microwave-assisted saponification 
reaction to increase solubility of the 
final compounds.  
4.2.d. 2-([1,1'-biphenyl]-4-carboxamido)benzoic acid derivatives prevent 
inflammatory cytokine production in primary macrophages stimulated with A.a LPS  
Derivatives were monitored for in vitro immunosuppressive activity using the 
previously described periodontal disease inflammation model232 using primary murine 
macrophages. 22, 24, 32 caused a significantly reduced secretion of the pro-inflammatory 
cytokine, IL-6, in response to A.a LPS. (Figure 4.4A) resulting in an overall hit rate of 20%. 
Compounds that significantly reduced inflammatory cytokine production compared to 
DMSO controls as determined by one-way ANOVA with multiple comparisons were set as 
actives while those that did not were set as inactives. These data were consolidated into 
a binary quantitative structure activity relationship, where descriptors were chosen based 
on contingency analysis (Table 4.2). Overall the model had an accuracy of 100% with a 
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60% chance value. This model had an 100% accuracy to predict active hits  with a 28% 
chance value and a 100% accuracy to predict inactive compounds with a 72% chance 
value (Figure 4.4B). The in silico library of derivatives was fit to this model and yielded 30 
potential hits with greater than 70% chance of being active, one of which was one of our 
current leads, compound 42. (Figure 4.4C) More importantly, several hits were eliminated 
from the pool of potential hits with high confidence. 
4.2.e. A binary quantitative structure activity relationship guided synthesis of potent 
immunosuppressors using phenotypic screening data 
Our second generation (34-42) of inhibitors was synthesized (Table 4.1) and 
compound 35, 38-40 and 42 significantly reduced the secretion of IL-6 in response to A.a 
LPS in vitro. (Figure 4.4) The current lead compounds 44 and 46 were further evaluated 
 
Figure 4.5. Potent immunosuppressive compounds do not inhibit KDM4B in biochemical assays, but show 
functional suppression of KDM4B activity in vitro. KDM4B activity was measured using an AlphaLISA® assay 
with experimental inhibitors 44 and 46, exhibiting an IC50 >100 μM.  (A) H3K9me3 (B) and H3K4me2 (C) protein 
abundance was quantified in RAW264.7 macrophages 24h following A.a LPS challenge. Cells were fluorescently 
stained and 36 images per well were captured using a Hermes Wiscan imaging system. Total fluorescence intensity 
was normalized to cell number and statistical significance was determined using a one-way ANOVA with multiple 
comparisons. N=3, 36 images per well. *p<0.05, **p<0.01, ***p<0.001. 


























































































































































































because of their potent immunosuppressive action rivaling that of the control compound, 
1. Surprisingly, using an AlphaLISA® KDM4B assay, we found that these compounds had 
no inhibitory activity for KDM4B at concentrations as high as 100μM. (Figure 4.5A) On 
the other hand, when we measured histone methylation marks as functional readouts in 
response to inhibitor treatment in vitro, we found that 42 and 46 were able to significantly  
increase H3K9me3 protein expression in vitro. (Figure 4.5B. D) Interestingly, while ML324 
pre-treatment resulted in the expected decrease in H3K4me2, 16, 42 and 46 all caused a 
significant increase in this mark. (Figure 4.5C, D) This suggests that these inhibitors may 
target a similar enzyme with additional activity at H3K4me2 or may indirectly cause 
inhibition of KDM4B through a process that is poorly recapitulated in biochemical assays 
using recombinant protein.  
 
Chapter 5: General Discussion and Future Directions: 
5.1. General Discussion 
To date, there is limited mechanistic data concerning the epigenetic modulation of 
periodontal inflammation. A 2014 study by Meng et al. used a novel BET bromodomain 
inhibitor, JQ1, in an experimental periodontal disease model and found that a decrease in 
BRD4 recruitment led to a reduction in periodontal inflammation and subsequent bone 
loss.244  Importantly, there have been no studies that suggest that any of the histone 
demethylases play a direct role in the progression or persistence of periodontal disease, 
despite the fact that numerous links between the KDM4 family of epigenetic modifiers and 
inflammation have been published. The study described herein demonstrates that 




lipopolysaccharide in macrophages. This effect occurs through new protein synthesis and 
a subsequent overactivation of KDM1A. In the absence of KDM4B, macrophages do not 
produce these inflammatory signals, and thus modulation of KDM4B activity could be 
utilized to locally suppress the immune response to plaque and microbial biofilms in PD 
patients for the resolution of inflammatory disease states.  
To determine whether KDM4B inhibition could be used as a therapeutic strategy 
to manage periodontal disease, we first demonstrated that the abundance of KDM4B 
protein is significantly increased in areas of inflammatory infiltrate marked by increased 
F4/80+ macrophage cells and increased tartrate resistant acid phosphatase (TRAP)+ 
osteoclastic cells following live A.a. subcutaneous injection into murine calvariae (Figure 
3.1A).245 The murine genome does not express KDM4E,246 leading us to believe that the 
ML324-induced immunomodulatory effect is entirely dependent on KDM4B. However, it is 
likely that ML324 would also interact with KDM4E when administered in humans. Thus, 
we sought to determine whether one or both of these enzymes were overproduced in 
periopathogen-activated immune cells using human clinical PD tissues. Our results 
demonstrate that the abundance of both KDM4B and KDM4E protein is significantly 
increased in the oral epithelium of patients with periodontal disease, compared to healthy 
controls. (Figure 3.1B).  
Based on computational studies, ML324 demonstrated promising selectivity for 
KDM4B (Figure 3.2A). Additionally, within the first 500 least energy docked poses, ML324 
did not enter the active site of either KDM4A or KDM4C. ML324 is a methyl derivative of 
the 8-hydroxyquinoline compounds developed as selective KDM4B inhibitors, yet thus far 
the drug has only been published as an inhibitor of KDM4E with an IC50 of 920 nM. The 




detail in the Experimental section. Herein we show that ML324 has additional inhibitory 
activity towards KDM4B, with an IC50 value of 4.9 μM (Figure 3.2B)247 and an EC50 value 
for its immunosuppressive action in vitro of 31.0 μM (Figure 3.2C). JIB-04 is a pan Jumonji 
domain demethylase inhibitor that inhibits KDM4B with an IC50 of 435 nM, but is a more 
potent inhibitor of the related demethylases JARID1A and KDM4E. Another KDM4B 
inhibitor, NSC636819, has been identified with a substantially higher IC50 against KDM4B 
of 9.3 μM. These data identify ML324 as a potent inhibitor of KDM4B with moderate 
selectivity that can be used as a tool to study phenotypic changes resulting from KDM4B 
inhibition. 
We thus reasoned that the periodontal immune response might be attenuated in 
the absence of KDM4B activity. Macrophages have been established as the primary 
mediator of the acute PD inflammatory response.248-250 For this reason, murine bone 
marrow derived macrophages (BMDMs) have been utilized extensively to model oral 
inflammatory responses. The pro-inflammatory cytokines TNF-α and IL-6 are classically 
up regulated in gingival connective tissues of PD patients, 36 and these cytokines are 
secreted from periopathogen activated macrophages through toll like receptor (TLR) 
signaling.225 Lipopolysaccharide (LPS) is a predominate surface antigen that activates this 
pathway; 251-252 therefore Aa-LPS, a well characterized periopathogen251-252 was used to 
simulate the immune challenge present in PD. We anticipate that KDM4B inhibition will be 
useful clinically following standard of care treatment (scaling and root planing (SRP)), 
where cells are primed for responding to inflammatory stimuli but are temporarily halted 
due to the elimination of the plaque biofilm. Introduction of an adjuvant therapy directly 
after SRP allows for modulation of the host immune response that can prevent future 




patients resume building biofilms back almost immediately after clinical intervention, we 
felt that a 1 hour pre-treatment would recapitulate the clinical setting most likely 
encountered by PD patients. Our results show that ML324-induced inhibition of KDM4B 
significantly suppresses the inflammatory response to bacterial LPS (Figure 3.3). TNF-α 
mRNA at 8h after Aa-LPS challenge was the only time point tested that did not produce a 
statistically significant effect, and this was consistent between both male and female cells 
(Figure 3.3). This suggests that TNF-α and IL-6 are epigenetically regulated differently 
due to the differences seen between groups in these cytokines.  
An additional component of the pathogenesis of periodontal disease is the 
imbalance in osteoimmunological mediators, resulting in a net loss of alveolar bone. 
KDM4B was recently shown to drive mesenchymal stem cells towards an osteogenic 
lineage preferentially over adipogenesis,253 but it is unknown how KDM4B regulates 
osteoclastic cell types. Because we have seen a decrease in inflammatory mediators 
required for endogenous osteoclastogenesis, we hypothesized that inhibition of KDM4B 
would also reduce osteoclastogenesis. Our data demonstrates that osteoclastogenesis 
proceeds normally with supplementation of either Aa-LPS or RANK-L, but when KDM4B 
is inhibited in pre-osteoclasts using ML324, neither of these additives induce significant 
osteoclast formation compared to vehicle control (Figure 3.4). This effect is seen in cells 
from both sexes, although there is a significantly higher number of osteoclasts formed in 
male cells compared to female cells, consistent with previous literature254 (Figure 3.4C). 
The mechanism by which KDM4B inhibition promotes immunosuppression is 
unknown. A study by Whetstine et al. demonstrated that KDM4B is structurally distinct 
from its other family members, and has the lowest demethylase activity of the KDM4 




demethylate non-histone proteins, many of which are transcriptional repressors.256 We 
used the NCBI Gene Expression Omnibus databank to determine the differences in 
expression of the KDM4 family of enzymes following lipopolysaccharide treatment in 
primary BMDMs. We found that the expression level of these enzymes doesn’t reflect their 
activity, as there are no significant differences in the expression of any KDM4 family gene 
between LPS treated cells and vehicle treated cells (Figure 3.6). Therefore, we probed 
methylation marks rather than expression of KDM4B itself to determine the mechanism of 
action of ML324. The RAW264.7 macrophage cell line is the best representation of 
primary bone marrow derived macrophages,227 but exhibit increased resiliency for use with 
glass plates for fluorescent imaging and highly cytotoxic chemicals such as cycloheximide. 
Herein we used immunofluorescent staining for methylation marks as well as 
cycloheximide treatment to show that KDM4B-induced immunosuppression acts via an 
indirect mechanism.257 After ML324 pre-treatment and Aa-LPS challenge in the presence 
of cycloheximide, the immunosuppressive effects of ML324 are completely abolished 
(Figure 3.5A). Additionally, it appears that when ML324 is added, even more IL-6 and 
TNF-α are being transcribed in response to Aa-LPS (Figure 3.5A). We postulate that 
because the cells are not able to effectively propagate intra- and inter-cellular signaling 
events, the transcripts are aberrantly abundant. Although the immunosuppressive activity 
of KDM4B inhibition requires new protein synthesis, an epigenetic mechanism is still at 
play, as evidenced by the increase in H3K9me3 and H3K4me levels that are reversed 
when KDM4B is inhibited (Figure 3.5B, C).  
We were able to recapitulate our in vitro data in vivo using a murine calvarial model 




PD: the ligature induced periodontal disease model is too acute for drug studies, while the 
alveolar LPS injection model is not as robust and has unavoidable experimentalist 
variability. Correlating with decreased osteoclastogenesis, we saw a decrease in bone 
loss following A.a injection with both ML324 and E3ii treatment as well as an increase 
between PBS vehicle and A.a treated mice. Tissues overlying the injection site were found 
to have increased amounts of H3K9me3 in ML324 treated animals, but this wasn’t affected 
by A.a injection alone, as was previously seen in vitro.  
These data together demonstrate that newly synthesized protein signals KDM1A 
following KDM4B inhibition, resulting in reduced transcriptional processing of pro-
inflammatory cytokines as well as reduced osteoclast formation.  This translates to 
reduced bone loss in vivo, which suggests that KDM4B inhibition could be a viable 
therapeutic option for treating periodontal disease induced bone loss. 
Drug discovery in the field of periodontics currently lacks momentum, and the 
minimal drug discovery that does go on frequently recycles drugs used for other purposes 
such as NSAIDs and antibiotics. We sought to utilize the well-established 
interconnectedness of histone 3 lysine 9 methylation with the immune system to develop 
drugs that could prevent the aberrant immune response that drives periodontal damage.  
ML324 was originally published as a KDM4E inhibitor,212 and therefore exhibits 
poor selectivity. This compound also suffers from extremely poor solubility. To enhance 
both of these properties, we utilized an in silico docking approach to identify several hit 
compounds for optimization. Our strategy utilized the consensus hits between multiple 
docking algorithms within two different software programs (DOCK6.5 flexible dock and 




negatives. Prior to docking, we selected the ZINC library containing compounds with 
predicted in vitro activity that were also available for sale. We filtered this compound library 
by eliminating compounds that were not drug-like following Lipinski’s rules, had many 
rotatable bonds and thus, had predicted cytotoxicity, and compounds that were not easy 
to synthesize in a high throughput manner (Figure 4.1). This refined library was docked 
into the active site of KDM4B and hits that ranked highly (>70th percentile) within both 
programs were subjected to physicochemical clustering.220 We generated a set of 
OpenBabel descriptors for each compound and clustered them based on similarity to 
eachother as well as similarity to known KDM4B inhibitors (ML324212 1, JIB-04242 2 and 
NSC636819243 3). We selected the smallest grouping that contained all three of these 
inhibitors and made sure that this grouping did not contain the control compound, a 
KDM1A inhibitor. (Figure 4.1)  
We screened the purchased hits using a previously published232 periodontal 
disease immunosuppression model using primary murine macrophages challenged with 
Aggregatebacter actinomycetemcomitans lipopolysaccharide for 24 hours following 1 hour 
pre-treatment at 50 μM with each compound. It is of critical importance in these 
experiments to use primary cells from normal mice as KDM4B has been established as a 
therapeutic target for anti-cancer agents.243, 258 Our experiments yielded several potential 
hits from our initial screen of several different chemotypes including anti-anxiolytic 
cinazepam259 13 and anti-tuberculosis drug aconiazide260 14. We ultimately selected 2-
([1,1'-biphenyl]-4-carboxamido)benzoic acid 16 due to its potency, solubility, ease of 
derivatization as well as ease of overall synthesis. We divided the scaffold into three units, 




library in silico based on commercially available and economical starting materials. Our 
initial library was subjected to consensus docking to prioritize our synthetic efforts. Despite 
our awareness of the power in using this tool, we ultimately synthesized both compounds 
with high binding affinity as well as compounds that we were able to synthesize efficiently. 
For example, the parent scaffold (scaffold 1) had a simplified synthetic scheme because 
of the purchasability of a two ringed starting material, eliminating the bulk of the synthetic 
difficulty. 
The Suzuki coupling reaction resulted in homocoupling of the bromobenzene 
starting material, which had been previously reported.261 Additionally, the third step 
sometimes generated an anyhydride product for selected diphenyl carboxylic acids. We 
hypothesize that the nucleophilic amine starting material was stabilized by the carboxylic 
acid hydroxy group, reducing its nucleophilicity and hydrophilicity making both the reaction 
and purification extremely difficult. Because of this, several hits were synthesized based 
on our ability to purchase starting materials that eliminated steps in our method (biphenyl 
carboxylic acids 19, eliminating the Suzuki coupling and ester cleavage reactions) as well 
as compounds that were very reactive or could be used in heavy excess due to the high 
yield of the previous step.  
Our synthetic method (Scheme 4.1) was relatively simple and utilized microwave assisted 
reactions to reduce the total time for synthesis. Purification of the three-ringed product 22 
from the amine starting material 21 proved unexpectedly difficult, likely due to strong 
hydrogen bonding between the amine hydrogen and the lone pairs of the adjacent acetate 
oxygen. For this reason, reactions were crystallized rather than purified by column 




starting material 21 as well as removing the excess oxalyl chloride prior to adding the 
nucleophilic amine 21 were critical for the success of this step. To do this more efficiently, 
we used dry DCE rather than DCM as was previously published,224 due to its higher boiling 
point. At this point, all reactions were bright yellow in color. For the next step we pre-stirred 
triethylamine with the amine 21, and this solution was added via cannula transfer to the 
reaction under nitrogen. When using lower equivalents of TEA the reaction did not 
proceed, likely due to strong hydrogen bonding between the amine hydrogen and the lone 
pairs of the adjacent acetate oxygen which decreased the nucleophilicity of the amine. 
When successful, the reaction proceeded almost instantaneously, with a sharp color 
change and white gas occurring in almost every reaction. Unfortunately, the final step was 
critical to the solubility of our final compounds. Thus, the ester 22 of each drug could not 
be considered for in vitro testing due to poor solubility. Purity of our final compounds was 
confirmed using UPLC, and compounds were characterized by NMR. Final compounds 
were only utilized for biological evaluation if purity was >95% by UPLC. 
We utilized the immunosuppressive action (Figure 4.4A) of the first 16 (16, 23-37) 
compounds synthesized to build a quantitative structure activity relationship (Figure 4.4B) 
utilizing 11 descriptors. We chose to use contingency analysis for selection of descriptors 
so that our methodology would be reproducible. We had a 20% hit rate with a 100% 
probability to predict negative hits but only a 88% probability to predict positive hits. This 
model was used to guide synthesis of 9 more compounds (38-46), several of which 
showed a significantly higher efficacy than the first series of inhibitors (Figure 4.4A), with 
a hit rate within our second generation of 56% yielding an overall hit rate of 29%. We 




screening (44, 46) for KDM4B inhibitory action and surprisingly found that they exhibited 
IC50 values >100 μM.  
Conclusion 
ML324 is an effective inhibitor of KDM4B, which acts through binding to KDM4B 
and initiating de novo protein synthesis, subsequent KDM1A activation followed by H3K4 
demethylation. This results in a reduced cytokine inflammatory response and decreased 
osteoclastogenesis in primary bone marrow cells. These data together provide a novel 
mechanism of immunomodulation through epigenetic modification, which can be used for 
further development of therapeutics for treatment of hyper-inflammatory disorders such as 
periodontal disease.  
We were able to use high-throughput computational chemical consensus screens 
coupled with in vitro phenotypic screening to identify novel compounds that cause 
immunosuppression coupled to epigenetic changes. We optimized these with our 
phenotypic screening data to identify multiple potent compounds. We conclude that novel 
scaffolds have been identified that could serve useful in treating periodontal disease 
through a unique epigenetic mechanism. 
5.2. Future Directions 
5.2.a. Further drug development 
This dissertation describes the identification of a novel scaffold for immunosuppressive 
drugs that could be used to treat hyper inflammatory disorders including periodontal 
disease. Additionally, this dissertation validated KDM4B as an epigenetic enzyme that 
produces immunosuppressive effects when inhibited in vitro and in vivo. Unfortunately, 




and our immunosuppressive compounds do not work through inhibition of KDM4B. Further 
drug discovery research should be conducted using enzymatic assay-based QSAR that 
correlates IC50 with structural characteristics rather than phenotypic immunosuppression 
which can be vague and off-target.  
5.2.b. Human samples 
While human tissues were stained immunohistochemically for KDM4B protein abundance 
from periodontally diseased and healthy tissues in this dissertation, no further human data 
was acquired. While there are obvious benefits associated with using a murine system to 
study periodontal disease such as cost, simplicity, sentience and complete genetic control, 
there are equally obvious limitations. For example, mice do not develop periodontal 
disease and are not naturally colonized with periodontal pathogens such as 
Porphyromonas gingivalis or Aggregatibacter actinomycetemcomitans. Because of this, it 
would be more clinically relevant to measure the efficacy of KDM4B inhibition to cause 
immunosuppression in human tissues or cells. Future studies should incorporate the use 
of either an immortalized human cell line or even a human macrophage cancer cell line 
such as KG-1 cells.  
5.2.c. Assay development 
As mentioned previously, the quantitative structure activity relationship that was 
developed through completion of this dissertation is binary and is based on statistically 
significant phenotypic immunosuppression data. While this type of screening produces 
clinically applicable inhibitors, the potential for development of drugs that are off-target is 
very high. This strategy was utilized due to the limited options available for biochemically 




alphalisa or AlphaScreen assay which is costly and requires an advanced alpha count 
reading plate reader. Future work should focus on development of a more economical 
enzyme assay, or at the very least the growth of KDM4B protein in E. coli.  
5.2.d. CRISPR/Cas9 
While we feel confident that KDM4B inhibition presents a valid therapeutic strategy for 
treatment of inflammatory diseases through the data presented within this dissertation, 
genetic deletion of KDM4B would be a worthwhile endeavor in the multitude of cell types 
involved in periodontal disease pathogenesis. As drug discovery toward KDM4B inhibitors 
gains momentum and more potent inhibitors are developed, it is prudent to understand 
the systemic effects of deletion of KDM4B in both health and disease states. Several 
groups have successfully deleted KDM4B through the use of CRISPR/Cas9 technology, 
but it has yet to be done in macrophages or in an inflammatory setting. These studies 
would help determine whether KDM4B inhibition is feasible, the extent of compensatory 
mechanisms among the KDM4 enzyme family, and potential positive or negative feedback 
mechanisms that may come into play with long-term KDM4B inhibition therapy. 
5.2.e. Macrophage polarization 
Initial studies were conducted within this dissertation towards understanding the 
polarization of macrophages following KDM4B inhibition. Unfortunately, these studies 
were contradictory, and no definitive conclusions could be made. Macrophages treated 
with KDM4B inhibitors secrete less pro-inflammatory cytokines, increased IL-10, an anti-
inflammatory cytokine, do not morphologically look like M1 macrophages when stimulated 
with LPS, and have a metabolic profile consistent with depolarized M0 or M2 




macrophage polarization, therefore it is entirely possible that KDM4B is also involved in 
this switch that is seen in periodontal disease pathogenesis. Future work should clearly 
delineate whether KDM4B inhibition depolarizes or de-differentiates macrophages or if it 
induces M2 macrophage polarization. This could be done using cell sorting experiments 
or immunofluorescent staining of M1 and M2 macrophage markers. 
5.2.f. Optimization and expansion of calvarial model 
The in vivo experimentation conducted in this dissertation was unfortunately limited to 
male mice only. This decision was made based on the lack of differences seen between 
male and female cells in their inflammatory response to LPS and whole bacteria following 
KDM4B inhibition. Differences were observed in osteoclastogenesis between male and 
female cells in response to KDM4B inhibitors. These differences were seen with and 
without KDM4B inhibition, and previous literature has described differences between male 
and female osteoclastogenesis. While these facts validate the use of a single sex for 
preliminary experimentation, testing should be done in both male and female mice prior to 
translation to clinical studies. 
Additionally, the A.a induced bone loss observed in our experimentation was not robust 
enough to determine significant differences between groups. A pilot study should be 
conducted that includes a dose-response to fixed A.a and experiments should be 
repeated. The most potent immunosuppressor, compound 46, should also be tested in 
vivo. 
5.2.g. Additional Disease models 
Because the general idea of KDM4B inhibitors as therapeutics for periodontal disease is 




could be used for various additional hyper-inflammatory diseases. For example, 
rheumatoid arthritis is a common degenerative disease driven by the immune response 
and affects more than 21% of the adult American population and would thus present a 
potential candidate disease that could be treated using KDM4B inhibitors. Additionally, as 
mentioned previously, periodontal disease has been linked to even more prevalent 
systemic diseases such as diabetes and obesity, for which an epigenetic mechanism 
underlying their interconnectedness has not been explored. A challenge with treatment of 
other diseases is the issue of systemic administration – in fact, the major appeal of 
epigenetic therapy for periodontal disease is the ability to provide local treatment directly 
in the oral cavity. Therefore, future work should focus on the potential effects of systemic 
KDM4B inhibitor administration. 
5.3. Impact on the field 
This project has several important implications that will make a significant impact across 
several fields, including periodontics, immunology and epigenetics. First, the regulation of 
periodontal disease by the epigenetic histone demethylase KDM4B was entirely unknown 
prior to completion of this dissertation. This project demonstrated that KDM4B plays a 
regulatory role in both perio-pathogen induced inflammation as well as bone loss. Prior to 
this study, host modulation therapy for treating periodontal disease through histone 
demethylase inhibition has yet to be translated into a pre-clinical model of the disease. 
This project resulted in a series of small molecule epigenetic modulating drugs and 
ultimately these compounds were tested in vivo. The synthetic methodology described in 
this dissertation has been optimized for development of additional inhibitors, to enable 




series of inhibitors that was developed, this project defined ML324 as a KDM4B inhibitor 
for the first time and extended the therapeutic potential for this drug to include reduction 
of inflammation and bone loss. Also, this project further confirmed the mutual exclusivity 
of the epigenetic enzymes KDM1A and KDM4B. The epigenetic landscape is extremely 
complex and yet to be completely understood; therefore, studies that elucidate interactions 
between epigenetic mechanisms are critically important. Overall, this project was able to 
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